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II Information on the structure of the thesis 
This thesis is divided into three main chapters (1) Introduction, (2) Results and (3) 
Summarizing discussion. 
 
The first chapter introduces the reader into the basic knowledge about iron oxide 
nanoparticles and brain astrocytes and gives a short review on the current scientific 
research status. 
 
The second part presents the results obtained during the laboratory work of this thesis. 
This chapter is divided into six sub-chapters containing publications/manuscripts that 
describe uptake, reactivity and biocompatibility of iron oxide nanoparticles in brain 
astrocyte cultures. The sub-chapters 2.1 to 2.4 contain already published articles which 
are embedded as portable document format in this thesis. The sub-chapters 2.5 and 2.6 
contain two manuscripts that were submitted for publication. These manuscripts were 
included in the thesis in the style as they were submitted for publication. However, the 
running text of the manuscripts was adjusted to the layout of this thesis and the figures 
and tables were positioned together with their legends directly after the respective 
results parts. 
 
The third part of the thesis presents a summarizing discussion of the key-findings of the 
investigations performed. Furthermore, it presences an outlook for future studies on the 
topic. 
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III Summary 
Magnetic iron oxide nanoparticles (IONPs) are used as tools for a wide range of 
biomedical and (neuro)biological applications, for example as contrast agent in 
magnetic resonance imaging, as transporter for drug delivery across biological barriers 
or for cancer treatment by magnetic field-induced hyperthermia. However, the 
knowledge on the effects of such particles on brain cells have only recently been 
addressed. This thesis describes the synthesis and characterization of citrate- and 
dimercaptosuccinate (DMSA)-coated IONPs. In addition, the uptake, reactivity and 
biocompatibility of such particles were investigated for astrocyte-rich primary cultures 
as a model system for brain astrocytes. Citrate- and DMSA-coated IONPs were 
accumulated by viable cultured astrocytes in a time- and concentration-dependent 
process leading to more than 100fold elevated specific cellular iron contents. Electron 
microscopy revealed that IONPs were present in intracellular vesicles as well as 
attached extracellularly to the cell membrane. Lowering the incubation temperature to 
4°C reduced the iron accumulation to about 50% which represented almost exclusively 
membrane associated extracellular IONPs. Presence of an external magnetic field 
increased the amount of cellular iron by 2-4fold, while presence of serum strongly 
reduced IONP-accumulation by up to 90% compared with the respective controls. 
Application of endocytosis inhibitors revealed that clathrin-mediated endocytosis and 
macropinocytosis contributed to IONP-uptake in serum-containing conditions. 
However, additional mechanisms are responsible for IONP-uptake under serum-free 
conditions. Prolonged presence of IONPs in cultured astrocytes for up to 7 d after a 
transient loading period of 4 h neither compromised cell viability nor affected basic 
metabolic pathways. However, a transient formation of reactive oxygen species and a 
delayed upregulation of cellular ferritin indicate that iron ions were liberated from the 
accumulated particles. In summary, this thesis revealed that viable astrocytes efficiently 
take up and safely store IONPs and IONP-derived iron, supporting the view that such 
particles can be used as save tools for diagnostic or therapeutic approaches in the brain. 
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IV Zusammenfassung 
Magnetische Eisenoxid-Nanopartikel (IONPs) werden für ein breites Spektrum an 
biomedizinischen und (neuro)biologischen Anwendungen eingesetzt, wie zum Beispiel 
als Kontrastmittel in der Kernspinresonanztomographie, als Transporter für 
Pharmazeutika über biologische Barrieren oder zur Bekämpfung von Krebs mittels 
Magnetfeld-induzierter Hyperthermie. Kenntnisse über die Effekte solcher Partikel auf 
Gehirnzellen wurden allerdings erst kürzlich erworben. Diese Arbeit beschreibt die 
Synthese und Charakterisierung von Citrat- und Dimercaptosuccinat (DMSA)-
umhüllten IONPs. Außerdem wurden Aufnahme, Reaktivität und Biokompatibilität 
solcher Partikel in Astrozyten-reichen Primärkulturen als Modellsystem für die 
Astrozyten des Gehirns untersucht. Citrat- und DMSA-umhüllte IONPs wurden von 
vitalen Astrozyten in einem zeit- und konzentrationsabhängigen Prozess akkumuliert, 
welcher zu einem mehr als 100fach gesteigerten spezifischen zellulären Eisengehalt 
führte. Elektronenmikroskopie zeigte die Präsenz von IONPs in intrazellulären Vesikeln 
sowie IONPs, die extrazellulär an die Zellmembran gebunden waren. Absenken der 
Inkubationstemperatur auf 4°C verringerte die Eisenakkumulation auf etwa 50%, 
welche fast ausschließlich extrazellulär membrangebundene IONPs darstellen. Präsenz 
eines externen Magnetfeldes führte zu einer 2-4fachen Erhöhung des zellulären 
Eisengehaltes, während die Gegenwart von Serum die IONP-Akkumulation um bis zu 
90% im Vergleich zur jeweiligen Kontrolle verringerte. Der Einsatz von Endozytose-
Inhibitoren zeigte, dass Clathrin-vermittelte Endozytose und Makropinozytose an der 
IONP-Aufnahme unter Serum-haltigen Inkubationsbedingungen beteiligt sind. Darüber 
hinaus sind noch weitere Mechanismen an der IONP-Aufnahme unter Serum-freien 
Bedingungen beteiligt. Eine längere Präsenz von IONPs in Astrozyten für bis zu 7 Tage 
nach einer 4-stündigen Beladung führte weder zu einem Verlust an Zellvitalität noch zu 
Veränderungen in basalen Stoffwechselleistungen. Jedoch wiesen eine transiente 
Bildung reaktiver Sauerstoffspezies sowie eine verzögerte Hochregulation von 
zellulärem Ferritin die Freisetzung von Eisen-Ionen aus den akkumulierten Partikeln 
nach. Zusammenfassend zeigte diese Arbeit, dass vitale Astrozyten IONPs effizient 
aufnehmen und die Partikel und deren Eisen sicher speichern. Diese Befunde stützen die 
Ansicht, dass IONPs einen sicheren Einsatz für diagnostische und therapeutische 
Zwecke im Gehirn erlauben. 
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1. Introduction 
Nanotechnology gained a huge interest in the last decades and is expected to be one of 
the major industries of the 21
st
 century (Mangematin & Walsh 2012). By some 
estimates, it will become a $2.5 trillion market by 2015 (Invernizzi 2011). Nanoparticles 
(NPs) are defined as particles which have a size of 1 to 100 nm in two or three 
dimensions (Auffan et al. 2009). Due to their small size, physical and chemical 
properties of NPs are likely to differ from the respective bulk/macroscopic material 
(Auffan et al. 2009). 
 
NPs can consist of various materials. One important type of NP which became popular 
in the 1980s was the by Sir Harold W. Kroto and colleagues discovered C60-Fullerene, a 
carbon NP made of 60 C-Atoms (Kroto et al. 1985). Another interesting type of carbon-
based nanostructures are the so-called carbon nanotubes (Iijiama 1991), which have 
been considered for applications in neurobiology (Malarkey & Parpura 2010). 
Furthermore, also the industrially produced carbon black contains NPs (Berg et al. 
2010). 
 
Besides carbon, there is a wide range of metal or metal-oxide containing NPs. Such NPs 
usually consist of a core of the respective metal/metal oxide which is surrounded by a 
ligand shell. Due to their size, NPs show different properties compared to the respective 
bulk material or metal in solution. This gives them a wide range of possible applications 
for example as catalysts (Jia & Schuth 2011), antibacterial agents (Rai et al. 2009, 
Dastjerdi & Montazer 2010) or in cosmetic products (Kokura et al. 2010). 
 
 
1.1 Iron oxide nanoparticles 
Iron oxide nanoparticles (IONPs) contain a core of iron oxide which is surrounded by a 
shell of ligands (Lu et al. 2007, Laurent et al. 2008). Although there are more than ten 
described iron oxides, hydroxides and oxidohydroxides (Cornell & Schwertmann 1996), 
the core of the most IONPs contains either magnetite (Fe3O4) or maghemite (-Fe2O3). 
Due to the magnetism of these iron oxide modifications, magnetic IONPs have gained 
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high interest and a wide range of technical, biological and clinical applications (see 
1.1.4). However, also hematite (-Fe2O3) or even zero-valent iron NPs have been 
described (Zhang 2003, Rosicka & Sembera 2011, Xu et al. 2011). 
 
Various types of molecules have been used as ligands for IONPs. The type of ligand 
determines the surface chemistry and thus the behavior of the particles. Possible ligands 
(coatings) for IONPs can be divided into four groups: inorganic compounds, small 
organic molecules, polymers and proteins. Examples for these ligand-types and a 
description of the importance of the coating for the properties of IONPs are given in 
chapter 1.1.2. 
 
 
1.1.1 Synthesis 
There is a large number of methods described for the synthesis of IONPs (Gupta & 
Gupta 2005, Laurent et al. 2008, Mahmoudi et al. 2011). Besides numerous chemical or 
physical methods for the synthesis of IONPs, also bacterial synthesis involving 
biomineralization have been described. An overview on important methods used to 
synthesize IONPs is given in Table 1.1. 
 
Table 1.1: Selected methods for synthesis of IONPs. 
Type of method Description Selected reference 
Chemical Co-precipitation Massart 1982 
 Microemulsions Chin & Yaacob 2007 
 Thermal decomposition Kwon et al. 2007 
 Sol-gel reactions Ennas et al. 1998 
 Polyol methods Cai & Wan 2007 
 Sonochemical methods Abu Mukh-Qasem & Gedanken 2005 
 Electrochemical methods Pascal et al. 1999 
Physical Flow injection Salazar-Alvarez et al. 2006 
 Aerosol / Vapor Pecharroman et al. 1995 
 Pulsed laser ablation Wang et al. 2006 
Biological Biomineralization Lisy et al. 2007 
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Since the synthesis via co-precipitation of ferrous and ferric iron in an alkaline 
environment is one of the most common methods and has also been used in this thesis, 
it will be described here in more detail. This method was originally described by René 
Massart about three decades ago (Massart 1982). In the co-precipitation technique, 
IONPs are produced by adding a base (NaOH, NH4OH or N(CH3)4OH) to an aqueous 
solution containing Fe
2+
 and Fe
3+
 ions, usually in a 1:2 stoichiometric ratio. Magnetite 
(Fe3O4) NPs are then generated by the following reaction scheme (Schwertmann & 
Cornell 1991): 
 
 Fe
2+
  +  2 Fe
3+
  +  8 OH

      Fe3O4  +  4 H2O 
 
Since magnetite is not very stable and sensitive to oxidation (Laurent et al. 2008), the 
generated NPs will be oxidized to maghemite (-Fe2O3) or ferric hydroxide (Fe(OH)3) 
according to the following reaction schemes (Mahmoudi et al. 2011): 
 
 Fe3O4  +  2 H
+
      -Fe2O3  +  Fe
2+
  +  H2O 
 Fe3O4  +  O2  +  H2O      3 Fe(OH)3 
 
As seen from the equations, oxidation of magnetite can occur by either oxygen or by 
proton transfer depending on the pH of the suspension. At acidic pH values, Fe
2+
 ions 
desorb from the NPs surface as hexa-aqua complexes in solution leading to the 
formation of maghemite (Laurent et al. 2008). It should be noticed here, that IONPs 
prepared by the co-precipitation method often contain mixtures of both magnetite and 
maghemite (Maity & Agrawal 2007). The size, shape and composition of the IONPs 
formed depend on the experimental parameters applied, like the types of salts used, the 
Fe
2+
/Fe
3+
-ratio, the reaction temperature, the pH value and the ionic strength of the 
reaction medium (Lu et al. 2007). However, the synthesis of IONPs via the co-
precipitation method is highly reproducible as long as identical experimental conditions 
are used (Lu et al. 2007). 
 
Both iron oxides, Fe3O4 and -Fe2O3 are ferrimagnetic (Cornell & Schwertmann 1996). 
Thus, the synthesized NPs can easily be separated from the reaction mixture by 
decantation in the presence of an external magnetic field. When dispersed into a 
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solution, IONPs behave like a magnetic fluid in an external magnetic field, also called 
ferrofluid. Due to their small size, the IONPs are superparamagnetic (see. 1.1.3). 
 
 
1.1.2 Coating 
The stabilization of IONPs by surface coating is an important issue because these 
particles tend to aggregate/agglomerate when dispersed into high ionic strength solvents 
like biological media. This aggregation is a result of attractive forces between the 
particles, such as van der Waals forces and magnetic dipole interactions. On the other 
hand, IONPs can be stabilized in solution by electrostatic or steric repulsion forces 
(Laurent et al. 2008). The function of a proper surface coating for IONPs is to stabilize 
the particles in solutions (like biological media) by optimization of the two repulsive 
forces (Cornell & Schwertmann 1996, Laurent et al. 2008). 
 
Coatings for IONPs consist of various types of molecules and can be divided into four 
groups of coating material: inorganic molecules (atoms, ions), small organic molecules, 
polymers and proteins. Examples for coatings of IONPs are given in Table 1.2. 
 
Table 1.2: Selected coatings for stabilization of IONPs. 
Type of coating Example Selected references 
Inorganic Silica Bumb et al. 2008 
 Gold Lim et al. 2009 
Organic (monomer) Citric acid Bee et al. 1995 
Taupitz et al. 2004 
 Gluconic acid Fauconnier et al. 1999 
 Dimercaptosuccinic acid Fauconnier et al. 1997 
Organic (polymer) Dextran Bautista et al. 2005 
 Polyethlene glycol Zhang et al. 2002 
Barrera et al. 2009 
 Polyvinyl alcohol Petri-Fink et al. 2008 
 Polyvinyl pyrrolidone Lee et al. 2008 
Protein Fetal bovine serum Wiogo et al. 2011 
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Inorganic coatings 
Various types of inorganic coatings have been described for IONPs. The most important 
materials are gold and silica. These IONPs thus have a core of iron oxide which is 
surrounded by a shell of the inorganic material (Laurent et al. 2008). 
 
Gold-iron oxide core/shell NPs can be synthesized via reduction of Au
3+
 ions on an 
IONP surface. For example, Cui et al. synthesized Au-coated IONPs via mixing 
HAuCl4 · 4 H2O with an aqueous dispersion of IONPs and subsequent addition of 
NH2OH as a reducing agent. These NPs were used for immobilization of 
immunoglobulin G (IgG) and for detection of the hepatitis B antigen in blood (Cui et al. 
2005). Another report by Lim and colleagues described the synthesis of Au-coated 
IONPs by attachment of very small gold nanoparticles (1.5-3 nm in diameter) onto the 
surface of IONPs that had been modified with mercaptoundecanoic acid (Lim et al. 
2009). 
 
Another important inorganic coating material for IONPs is silica. Silica-coated IONPs 
are stabilized in two different ways: on the one hand sterically and on the other hand 
electrostatically, because of the negative charges of the coating (Sun et al. 2005, 
Laurent et al. 2008). Silica as coating-material is considered to generate IONPs which 
show a high biocompatibility (Mahmoudi et al. 2011). For example, it has been shown 
recently that silica-coated IONPs are less toxic than citrate-coated IONPs (Narayanan et 
al. 2011). Ferumoxsil (Leung 2004) is a commercially available silica-coated IONP that 
was already used for clinical investigations two decades ago (Hahn et al. 1990). The 
commercial product NanoTherm® contains 15 nm aminosilane-coated IONPs which are 
used for cancer treatment by magnetic field-mediated hyperthermia (Thiesen & Jordan 
2008, Rivera Gil et al. 2010). 
 
 
Organic monomeric coatings 
Different types of functional groups like carboxylates, phosphates or sulfates are known 
to bind to the surface of iron oxides or IONPs (Cornell & Schwertmann 1996, Sahoo et 
al. 2001, Lu et al. 2007). Best described in the literature are carboxylates as coating 
material. 
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Citric acid has frequently been used for coating of IONPs. It is assumed, that this acid 
adsorbs to the surface of the IONPs by coordinating with one or two of its carboxylate 
groups to the particles surface. The other one or two carboxylate group(s) are thus 
exposed to the solvent leading to a negative surface charge and also to electrostatic 
stabilization of the NPs (Lu et al. 2007). An important example for such NP which also 
had been used for clinical investigations is the so-called VSOP C184: a citrate-coated 
IONP with a core-diameter of 4 nm (Wagner et al. 2002, Taupitz et al. 2004). Bee and 
colleagues reported that the presence of citric acid during the synthesis of IONPs affects 
the diameter of the obtained particles (Bee et al. 1995). Newer reports show that citric 
acid not only affects the particle size but also the crystallinity of the iron oxides formed 
(Liu & Huang 1999, Lu et al. 2007). 
 
Besides citric acid, other small organic molecules containing carboxyl-groups have been 
described as coating material for IONPs. Gluconic acid, tartaric acid or 
dimercaptosuccinic acid (DMSA) have been shown to affect the colloidal stability of 
IONPs in aqueous solution at different pH values (Fauconnier et al. 1999). An 
interesting role plays hereby the compound DMSA. In addition to the two carboxylate 
groups, this compound contains two thiol (SH) groups. These SH groups can be 
oxidized to form disulfides, thereby leading to the formation of poly-DMSA-molecules 
that are assumed to form a cage-like structure around the core of the IONPs (Fauconnier 
et al. 1997, Valois et al. 2010). Free carboxylate groups exposed to the solvent give 
these DMSA-IONPs a negative charge at physiological pH and thus lead to electrostatic 
stabilization. A further advantage of DMSA-IONPs is that solvent-exposed SH groups 
can be used for coupling of thiol reagents (for example fluorescent compounds) onto the 
NPs surface. 
 
Other monomeric coatings for IONPs contain sulfate or phosphate groups (Portet et al. 
2001). For example Yee et al. functionalized IONPs with alkanesulfonic or 
alkanephosphonic acids (Yee et al. 1999). Characterization of these particles via 
infrared (IR) spectroscopy suggested a binding of these ligands to the IONP-core via the 
sulfate- or phosphate-groups, respectively. For the phosphate ligands, a monodentate 
and a bidentate binding to the iron oxide surface is discussed, while sulfate ligands bind 
only via one oxygen atom to the surface of IONPs (Yee et al. 1999). 
Introduction  Part 1 
 
 
8 
 
Organic polymeric coatings 
A wide range of polymers has been used for coating and stabilization of IONPs. 
Frequently used polymer coatings are based on polyethylene glycol (PEG), polyvinyl 
alcohol (PVA), polyvinyl pyrrolidone (PVP) or dextran. The coating of IONPs with 
polymers can either occur during the particle synthesis (in situ coating) or after 
synthesis in an individual second coating step (post-synthesis coating) (Laurent et al. 
2008). 
 
In 1993, Palmacci and Josephson described a method for in situ coating of IONPs with 
dextran during a co-precipitation process (Palmacci & Josephson 1993). The size of the 
obtained NPs varied between 10 and 50 nm, depending on the conditions applied for 
synthesis (Palmacci & Josephson 1993). A more recent publication by Jarrett and 
colleagues described the synthesis of 30 nm dextran sulfate-coated IONPs and their 
applications in magnetic resonance imaging (MRI) (Jarrett et al. 2007). Nowadays, 
several methods for synthesis of dextran-coated IONPs exist and such nanoparticles 
have a wide range of biomedical applications (Tassa et al. 2011). The commercial 
available products “Endorem” and “Resovist” contain dextran- or carboxydextran-
coated IONPs, respectively (Soenen & De Cuyper 2010). 
 
Because of its hydrophilicity, polyethylene glycol (PEG) is frequently used as coating 
material for the generation of water-soluble IONPs. Due to the terminal hydroxyl 
groups, PEG-coating can also be used to conjugate additional (biological) molecules to 
the NP surface (Mahmoudi et al. 2011). Tong and colleagues synthesized PEG-coated 
IONPs by preparing an iron oxide core via thermal decomposition and by subsequent 
ligand exchange with a PEG-derivative (Tong et al. 2010). A similar approach was 
described earlier by Barrera et al. using PEG-silane as coating material (Barrera et al. 
2009). PEGylation of IONPs has also been discussed to facilitate their blood-brain 
barrier permeability (Winer et al. 2011). 
 
Further polymers, which are often used as coating materials for IONPs are polyvinyl 
alcohol (PVA) or polyvinyl pyrrolidone (PVP). A study of Petri-Fink and colleagues 
investigated the colloidal stability of PVA-coated IONPs in cell culture media. Long-
time colloidal stability was observed for PVA-coated IONPs in serum-containing 
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culture media. In contrast, in serum-free media the IONPs were only stable for about 30 
min (Petri-Fink et al. 2008). PVA-coated IONPs are taken up by HeLa cells and appear 
to cause no toxicity (Petri-Fink et al. 2008). Liu et al. synthesized PVP-coated IONPs 
by the polyol process that had an average diameter of less than 5 nm and were 
superparamagnetic (Liu et al. 2007). In addition, phosphate-containing polymers like 
polyvinyl alcohol phosphate (PVAP) have been described as coating materials for 
IONPs (Mohapatra et al. 2006). 
 
 
Protein coatings 
Formation of protein-coated IONPs is often observed after dispersion of IONPs in a 
protein-containing (i.e. serum-containing) cell culture medium. This formation of a 
protein-corona around the NP core (Nel et al. 2009) is important, since it affects the 
interactions between the particles and cell-membranes. Literature data clearly show that 
the uptake of IONPs into cells strongly depends on the presence of serum in the medium 
(Chen et al. 2008). Besides this ‘spontaneous’ protein-coating, also the controlled 
stabilization of IONPs with proteins has been described. Wiogo and co-workers 
stabilized carboxyl-functionalized IONPs in cell-culture media by adding fetal calf 
serum (FCS) to the medium (Wiogo et al. 2011). In another report, Lim et al. stabilized 
Au-coated IONPs by additional coating with bovine serum albumin (BSA) (Lim et al. 
2009). 
 
 
1.1.3 Characterization 
Physical and chemical characterization of IONPs is a crucial issue, since small 
alterations in the particle properties might have large influences on their possible 
technical, biological or biomedical applications (Laurent et al. 2008). IONPs can be 
characterized by a wide range of physical and (physico)chemical methods. Frequently 
used methods to characterize properties of IONPs are given in Table 1.3. 
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Table 1.3: Methods to characterize IONPs. 
Method Parameter/properties investigated 
Electron microscopy Core size and morphology 
Energy dispersive X-ray spectroscopy Elemental composition 
Mößbauer spectroscopy Discrimination between Fe(II) and Fe(III) 
X-ray diffraction Crystal structure 
IR spectroscopy Detection of functional groups 
(surface coating) 
Dynamic light scattering Hydrodynamic particle size in dispersion 
Zeta-potential measurement Surface charge 
Magnetic susceptibility measurement Magnetism 
Magnetic resonance T1 / T2 – Relaxation times 
 
 
Size and shape of IONPs 
By definition, NPs have a size of less than 100 nm in two or three dimensions (Auffan 
et al. 2009). NPs with only two dimensions smaller that 100 nm and a third dimension 
that is much longer are called nanorods or nanowires (Cao & Wang 2004). The most 
suitable method to get information about the size and shape of NPs is electron 
microscopy. Mostly, transmission electron microscopy (TEM) is used for size 
determination. However, also X-ray diffraction, which is normally used to obtain 
information about the crystal structure, is suitable to investigate the particle size by 
using the Scherrer equation (Holzwarth & Gibson 2011). The frequently used photon 
correlation spectroscopy or dynamic light scattering (DLS) determines hydrodynamic 
diameters of NPs in dispersion and thus gives information about their colloidal stability 
(Aberle et al. 2002). 
 
IONPs that were synthesized by the classical co-precipitation route have a typical size 
of around 10 nm in diameter (Kang et al. 1996). However, the particle size can be 
modulated. For example, Bee et al. showed that the size of IONPs obtained in the co-
precipitation process can be lowered to ~2 nm when citric acid is added to the reaction 
mixture (Bee et al. 1995). Nowadays, numerous methods have been described for size 
controlled synthesis of IONPs (Lu et al. 2007). Besides the size, also the shape of the 
IONPs can be controlled during the synthesis. Classical synthesis routes lead to particles 
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that are roughly spherical in shape and have a polydisperse size distribution. However, 
methods have also been described to obtain monodisperse spherical IONPs (Hyeon et 
al. 2001, Park et al. 2007), iron oxide nanocubes (Yang et al. 2008, Kim et al. 2009, 
Wang & Yang 2009), nanorods (Li et al. 2009, Wang & Yang 2009) or even octahedral 
shaped IONPs (Li et al. 2010). 
 
 
Crystal structure of IONPs 
More than ten different iron oxides, hydroxides or oxidohydroxides have been described 
(Cornell & Schwertmann 1996). The most common iron oxides are the ferrous oxide 
Wüstite (FeO), the ferrous/ferric iron oxide magnetite (Fe3O4), the ferric oxides 
hematite (-Fe2O3) and maghemite (-Fe2O3). Magnetite and maghemite are both 
ferrimagnetic iron oxides (Cornell & Schwertmann 1996). This is the base for the 
magnetic properties of nanoparticular forms of these iron oxides. 
 
The crystal structure of IONPs can be determined via X-ray diffraction (XRD) (Brown 
1980). Since the distances between the atoms in a crystal structure are comparable to the 
wavelengths of X-rays, crystals diffract X-rays (Cornell & Schwertmann 1996). The 
diffraction pattern allows to determine the crystal structure and thus, the type of iron 
oxide. Typically IONPs consist of one of the magnetic iron oxides, either magnetite 
(Fe3O4) or maghemite (-Fe2O3), which both crystallize in the cubic structure (Cornell 
& Schwertmann 1996). Thus, it is difficult to distinguish between these two types of 
iron oxides via XRD. Since magnetite contains both – ferrous and ferric iron – whereas 
maghemite is fully oxidized to ferric iron, these oxides can de distinguished by 
Mößbauer spectroscopy (Woo et al. 2004). In addition to magnetite and maghemite 
IONPs, also hematite (-Fe2O3) IONPs have been described (Xu et al. 2011). -Fe2O3 
has a hexagonal (rhombohedral) crystal structure and is thus easily distinguishable from 
the other iron oxides by XRD (Cornell & Schwertmann 1996). The ferrous oxide 
Wüstite (FeO) is very sensitive to oxidation processes and thus is rarely found in 
IONPs. Wüstite IONPs often consist of FeO/Fe3O4 core-shell structures as determined 
by high resolution TEM (HR-TEM) and selected area electron diffraction (SAED) 
(Sharma et al. 2011). 
 
Introduction  Part 1 
 
 
12 
 
Magnetism of IONPs 
Magnetite (Fe3O4) and maghemite (-Fe2O3) are both ferrimagnetic iron oxides (Cornell 
& Schwertmann 1996). In a ferrimagnetic compound, the single particles (atoms, ions, 
molecules) carry a magnetic moment and these magnetic moments align to an ordering 
of two oppositely directed magnetic sublattices (Koksharov 2009). Since the sublattices 
are not identical and one has a higher magnetic moment than the other, the total 
magnetic moment does not vanish (Koksharov 2009). Thus, magnetic domains (so-
called Weiss domains) are formed which have a typical size ranging from a few 
nanometers up to one micrometer (Lu et al. 2007). When such a ferrimagnetic 
compound is exposed to an external magnetic field, the magnetic domains align and the 
compound gets magnetized. Ferro- and ferrimagnetic materials retain some of this 
magnetization which can be macroscopically measured. 
 
When the particle size of a compound is in the nanometer range, each particle will 
contain only one Weiss domain. They are randomly ordered, but will align when an 
external magnetic field is applied. When the field is removed, they will spontaneously 
randomize again due to the so called Brownian and Néel relaxation (Gittlema et al. 
1974). Thus, no retaining magnetization will be observed. The compound behaves like a 
paramagnet, which consists of magnetic moments and increases a magnetic field in its 
interior but looses it when the field is removed. This phenomenon is called 
superparamagetism. Superparamagnetic IONPs dispersed in an appropriate solvent 
behave like a magnetic fluid (Lu et al. 2007). 
 
 
1.1.4 Applications 
There are many applications of IONPs which take advantage of their different 
properties, such as their small size, surface chemistry or their magnetism. Applications 
of IONPs range from technical and engineering fields (i.e. their function as pigments, in 
catalysis or for magnetic storage media) to medical and (neuro)biological fields. In this 
thesis, only a short review about their most prominent applications in medicine and 
biology (especially related to the brain) will be given. A summary of these applications 
is shown in Table 1.4. 
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Table 1.4: Biomedical and (neuro)biological applications of IONPs. 
Application Selected references 
MRI contrast enhancement Weinstein et al. 2010 
Winer et al. 2011 
Targeted drug delivery Chertok et al. 2008 
Magnetic field-induced hyperthermia Thiesen & Jordan 2008 
Maier-Hauff et al. 2011 
Cell labeling / cell tracking Cromer Berman et al. 2011 
Magnetic transfection (magnetofection) Kamau et al. 2006 
Pickard & Chari 2010a 
 
 
The most common application of IONPs is their use as contrast agent in magnetic 
resonance imaging (MRI) (Weinstein et al. 2010, Winer et al. 2011). Iron oxide based 
contrast agents constitute the counterpart to the classical gadolinium (Gd)-based agents. 
While the latter ones affect the longitudinal (T1) relaxation processes, the IONP-based 
contrast agents reduce transverse (T2) relaxation times. This leads to contrast 
enhancement in T2/T2*-weighted MRI acquisitions by IONP-based contrast agents 
compared to Gd-based contrast agents which are used in T1-weighted MRI acquisitions 
(Weinstein et al. 2010). IONP-based contrast agents have a longer half-life which is an 
advantage for repeated imaging without subsequent administration of contrast agent 
(Winer et al. 2011). Furthermore they seem to be less toxic than Gd-based contrast 
agents, since the latter ones are known to cause nephrogenic systemic fibrosis in 
patients with renal insufficiency (Marckmann et al. 2006). Another advantage of IONP-
based contrast agents in brain tumor imaging is that IONPs which have penetrated the 
defective blood-brain barrier are endocytosed by reactive astrocytes or macrophages and 
remain there for several days (Murillo et al. 2005). Thus, repeated imaging of the brain 
without subsequent administration of contrast agent is possible. 
 
Due to their MRI contrast enhancing effect, IONPs have been used for effective cell 
labeling and cell tracking with the advantage of a high image resolution that did not 
require exposure to ionizing radiation for imaging (Cromer Berman et al. 2011). Cells 
can be labeled by various techniques, such as simple incubation of the cells with the 
particles or by application of transfection agents (Cromer Berman et al. 2011). The 
transfection efficiency of cells with IONPs can be facilitated with the aid of magnetic 
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fields (Kamau et al. 2006, Pickard & Chari 2010a). This magnetofection has also been 
successfully applied to cultured astrocytes (Pickard & Chari 2010a). 
 
Another large field of applications of NPs is the targeted delivery of drugs across the 
blood-brain barrier (Yang 2010). This barrier is formed by the endothelial cells of the 
brain capillaries which are connected via tight junctions (Abbott et al. 2010). Since 
more that 98% of small molecular weight drugs and almost 100% of large molecular 
weight drugs are not able to penetrate the blood-brain barrier (Pardridge 2002, Yang 
2010), targeted drug delivery is a big challenge for the future. Already more than ten 
years ago, it was shown that the anticancer drug doxorubicin could be successfully 
delivered to the brain by using polysorbate-80-coated poly(butyl-cyanoacrylate) NPs 
(Kreuter 2001). Also IONPs have been used as drug delivery vehicle for targeting of 
brain tumors with the aid of magnetic fields (Chertok et al. 2008). The magnetic drug 
targeting with IONPs is considered as promising technology for therapy challenges in 
the 21
st
 century (Kempe et al. 2011). 
 
Besides the delivery of drugs with the aid of IONPs, the particles themselves are a 
promising tool in anti-tumor treatment. In magnetic fluid hyperthermia (MFH), IONPs 
are injected into a tumor and the patient is then exposed to a high frequency (100 kHz) 
altering magnetic field. This treatment induces fast movements of the NPs and thus 
heating of NPs and the surrounding tumor tissue. The potential of small magnetite or 
ferrite particles as tool for MFH has already been described in 1993 (Jordan et al. 1993). 
In 2003, the first clinical study for treatment of brain glioblastoma multiforme by MFH 
with aminosilane-coated IONPs was started (Maier-Hauff et al. 2007, Thiesen & Jordan 
2008). Post-mortem studies of the brains of glioblastoma patients revealed the presence 
of remaining IONPs in the regions of instillation. The particles were mainly 
phagocytosed by macrophages and only a minority was taken up by glioma cells (van 
Landeghem et al. 2009).  Nowadays, there are several reports on clinical studies about 
treatments of glioblastoma or prostate carcinoma with MFH or with combinations of 
MFH and classical radiation therapy (Johannsen et al. 2005, Maier-Hauff et al. 2007, 
Thiesen & Jordan 2008, Maier-Hauff et al. 2011). 
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1.2 Astrocytes 
The mammalian brain is a highly complex organ containing different cell types 
(Figure 1.1) which can be mainly divided into two groups: the neurons and the glia 
cells. Although, glia cells make up most of the cells of the brain, they were considered 
for long times only to have a passive supporting role (Allen & Barres 2009). However, 
nowadays it has become clear, that glia cells have a huge variety of important functions 
in the brain. 
 
Astrocytes, which are strategically located between blood vessels and other brain cells, 
have various functions in metabolic support, signal transduction, protection of neurons 
and detoxification of xenobiotics (Parpura et al. 2012). Oligodendrocytes form the 
myelin sheaths around the neuronal axons which are important to protect the axons and 
to facilitate signal transduction (Bradl & Lassmann 2010, Miron et al. 2011). Microglia 
represent the immune cells in the brain which show phagocytotic activity (Graeber & 
Streit 2010, Tremblay et al. 2011) and ependymal cells cover the ventricles that are 
filled with cerebrospinal fluid in the brain (Del Bigio 2010). 
 
 
Figure 1.1: Different types of cells in the brain. The picture shows the neurons, 
which are responsible for signal transduction via the synapses, and the different types 
of glia cells. Astrocytes connect blood vessels and neurons, oligodendrocytes form the 
myelin sheaths around the neuronal axons and microglia cells are the phagocytes of 
the brain. The ependymal cells cover the ventricles in the brain. (Modified from Pfrieger 
& Steinmetz 2003). 
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1.2.1 Properties and functions 
Astrocytes belong to the glia cells and represent the most abundant cell type in the brain 
outnumbering the neurons by over fivefold (Sofroniew & Vinters 2010). Astrocytes got 
their name from their star-shaped morphology (gr. astron (): star), containing a 
cell body which extends several processes (Oberheim et al. 2012). Astrocytes can be 
divided into mainly two groups: the protoplasmatic astrocytes found throughout the 
grey matter and the fibrous astrocytes which are present in the white matter of the brain 
(Kimelberg 2010, Sofroniew & Vinters 2010). Via their endfeet processes, both types of 
astrocytes stand in contact with the blood vessels of the brain (Mathiisen et al. 2010, 
Sofroniew & Vinters 2010). Furthermore, astrocytes are in contact with synapses and 
nodes of Ranvier and are also connected by gap junctions with neighboring astrocytes 
(Peters et al. 1991, Sofroniew & Vinters 2010). Thus, astrocytes have a strategically 
very important position in the brain, being the first cells that encounter substances 
which have passed the blood-brain barrier and standing in contact with all other types of 
brain cells. 
 
A characteristic marker for astrocytes is the glial fibrillary acidic protein (GFAP), which 
was first isolated in multiple sclerosis plaques around 40 years ago (Eng et al. 1971, 
Eng et al. 2000). GFAP is the main intermediate filament protein of astrocytes 
(Middeldorp & Hol 2011). It is expressed in healthy astrocytes, but its expression is 
strongly enhanced in reactive astrocytes. Thus it is also considered as marker for 
reactive astrogliosis and CNS injuries (Sofroniew & Vinters 2010). Also astrocytes in 
cell culture express GFAP (Bock et al. 1977, Schmidt 2010). 
 
Brain energy metabolism is of great importance, since this organ consumes about 20% 
of the energy used by the human body, but accounts only for 2% of the body mass 
(Sokoloff 1960, Attwell & Laughlin 2001, McKenna et al. 2006). With their contacts to 
the blood vessels, neighboring astrocytes, neuronal axons and synapses, astrocytes have 
an ideal position to fulfill a variety of important metabolic functions in the brain (Barros 
& Deitmer 2010, Sofroniew & Vinters 2010). Via the GLUT1 transporter, astrocytes 
take up glucose from the blood, which can be metabolized into lactate via glycolysis 
and than exported and taken up by neurons, as described by the astrocyte-neuron lactate 
shuttle hypothesis (Pellerin & Magistretti 1994, Pellerin et al. 2007). Nevertheless, it 
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has been shown that in the brain neurons take up about half of the glucose directly via 
the transporter GLUT3 (Nehlig et al. 2004). In cell culture experiments neurons 
preferentially use either glucose or lactate as their main source of energy, depending on 
their stimulated or resting physiological state (Bouzier-Sore et al. 2006, Bak et al. 
2009). 
 
Besides their important metabolic functions in the brain, astrocytes also take up and 
release neurotransmitters (Eulenburg & Gomeza 2010, Parpura & Zorec 2010, Parpura 
et al. 2012). The astrocyte processes, which have contact to the synapses, express high 
levels of transporters for the uptake of neurotransmitters like glutamate, -aminobutyric 
acid (GABA) and glycine (Sattler & Rothstein 2006, Seifert et al. 2006, Sofroniew & 
Vinters 2010). Furthermore, astrocytes release neurotransmitters (=gliotransmitters) like 
glutamate, purines, GABA and D-serine depending on synaptic activity and astrocytic 
intracellular Ca
2+
 concentration (Sofroniew & Vinters 2010), thereby modulating 
synaptic transmission. The importance of astrocytes in neurotransmission is underlined 
by their inclusion into the concept of the so-called tripartite synapse that is composed of 
a pre- and post-synaptic neuron and an astrocyte (Araque et al. 1999, Halassa et al. 
2007). 
 
Astrocytes have important functions in the detoxification of peroxides in the brain. 
Since the brain consumes about 20% of the oxygen used by the body, generation and 
disposal of peroxides is a crucial issue (Dringen et al. 2005). By mainly use of both, 
catalase and the glutathione (GSH) system, cultured astrocytes are able to clear 
hydrogen peroxide efficiently with half times in the minute range (Dringen et al. 1999, 
Dringen et al. 2005). In addition, astrocytes provide neighboring neurons with 
precursors for neuronal GSH synthesis (Dringen 2009, Hirrlinger & Dringen 2010, 
Schmidt & Dringen 2012) thus playing an important protective role for neurons against 
oxidative stress. 
 
In addition to all these functions in metabolism, signal transduction and protection of 
neurons, astrocytes have important functions in the regulation of metal homeostasis 
(Tiffany-Castiglioni & Qian 2001, Dringen et al. 2007, Tiffany-Castiglioni et al. 2011). 
Quite a large number of information is now available about uptake, metabolism and 
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release of metals such as iron and copper in cultured astrocytes (Hoepken et al. 2004, 
Bishop et al. 2010, Scheiber et al. 2010, Bishop et al. 2011, Dang et al. 2011, Scheiber 
et al. 2012). Since the metabolism of iron is highly important for this thesis, the 
following chapter will summarize the iron metabolism of astrocytes. 
 
 
1.2.2 Iron metabolism 
Metal ions have a wide range of important functions in numerous biological processes 
such as energy production, neurotransmission, muscle contraction and oxygen transport 
(Crichton et al. 2011). For the central nervous system, iron plays a key role in many 
metabolic processes, including oxidative phosphorylation, myelin synthesis, 
neurotransmitter production, nitric oxide metabolism and oxygen transport (Crichton 
2009, Crichton et al. 2011). On the other hand, iron can be toxic to cells since low 
molecular weight ferrous (Fe
2+
) iron can catalyze the Fenton reaction in which hydrogen 
peroxide (H2O2) in converted to a hydroxyl anion (OH

) and the highly reactive 
hydroxyl radical (OH∙) (Dringen et al. 2007). 
 
Fe
2+
  +  H2O2      Fe
3+
  +  OH∙  +  OH 
 
Thus, the amount of free cellular ferrous iron has to be tightly regulated. 
 
 
Iron uptake into the brain 
In the blood circulation, up to two ferric (Fe
3+
) iron ions are bound to the iron transport 
protein transferrin. The diferric transferrin binds to the transferrin receptor (TfR) – 
which is expressed on the luminal side of the brain capillaries – and is then internalized 
into the endothelial cells by receptor mediated endocytosis (Crichton 2009, Crichton et 
al. 2011). Due to the lower endosomal pH value, the iron is liberated from transferrin 
and the apotransferrin gets recycled (Crichton et al. 2011). However, the exact 
mechanism of iron release from the endosomes of the capillary endothelial cells and of 
the entrance of iron into the brain is still under discussion since it is not clear if the 
divalent metal transporter 1 (DMT1) is expressed in brain capillary endothelial cells 
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(Burdo et al. 2001, Moos & Morgan 2004, Moos & Rosengren Nielsen 2006, Crichton 
et al. 2011). Nevertheless, the endothelial cells of the brain capillaries have to be able to 
release at least some iron to provide this essential metal to parenchymal brain cells. 
 
 
Iron metabolism of astrocytes 
Astrocytes, which cover with their endfeet the brain capillaries (Mathiisen et al. 2010), 
are the first cells which encounter substances released from endothelial cells into the 
brain parenchyma. It has been suggested, that astrocytes play an important role in the 
release of iron from the endothelial cells by providing citrate or adenosine triphosphate 
(ATP) to complex the released iron (Moos et al. 2007). Complexed iron will then 
circulate in the brain extracellular fluid before it is bound to transferrin and/or taken up 
by astrocytes or other types of brain cells. Uptake, metabolism, storage and export of 
iron have been quite well investigated for cultured astrocytes. A summary of the most 
important pathways involved in iron metabolism of astrocytes is given in Figure 1.2. 
 
Different pathways have been suggested for the uptake of iron into astrocytes. 
Transferrin bound iron can be taken up by receptor-mediated endocytosis via TfR as 
shown for cultured rat astrocytes (Qian et al. 2000, Hoepken et al. 2004, Dringen et al. 
2007). However, it has to be noticed that TfR appears not to be expressed in astrocytes 
in vivo (Moos et al. 1999, Jeong & David 2006), suggesting different routes for iron 
uptake into astrocytes in brain. Also, non-transferrin-bound ferric iron is taken up by 
cultured astrocytes (Keenan et al. 2010, Lane et al. 2010, Tulpule et al. 2010, Bishop et 
al. 2011). However, the mechanism of uptake of non-transferrin-bound ferric iron is still 
under debate. The divalent metal transporter 1 (DMT1) appears to be a suitable 
transporter for non-transferrin-bound ferrous iron. DMT1 is a proton co-transporter 
which is expressed in astrocytic endfeet in vivo as well as in cultured astrocytes (Burdo 
et al. 2001, Tulpule et al. 2010). Indeed, DMT1 contributes to the uptake of ferrous iron 
in cultured rat astrocytes (Lane et al. 2010, Tulpule et al. 2010). Since ferrous iron is 
rapidly oxidized to ferric iron at physiological pH, it is discussed that cultured 
astrocytes possess extracellular ferric reductase activity. Indeed, the mRNA of the ferric 
reductases duodenal cytochrome b (Dcytb) and stromal cell-derived receptor 2 (SDR2) 
were detected in cultured astrocytes (Tulpule et al. 2010). Another pathway of iron 
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uptake into astrocytes is the uptake of hemin, which contains ferric iron. The uptake is 
mediated by the heme carrier protein 1 (HCP1) which is expressed by cultured 
astrocytes (Dang et al. 2010). Hemin is then intracellular degraded in astrocytes by the 
heme oxygenase 1 (HO-1), leading to liberation of the iron (Dang et al. 2011). 
 
 
Figure 1.2: Iron metabolism of cultured astrocytes. Transferrin-bound iron can be 
taken up by transferrin receptor (TfR)-mediated endocytosis. Non-transferrin-bound 
iron can enter the cell by different pathways. Cultured astrocytes express the divalent 
metal transporter 1 (DMT1) that allows the uptake of ferrous iron into the cell. Ferric 
iron (for example as ferric ammonium citrate, FAC) can either be taken up directly or be 
reduced to ferrous iron by the extracellular ferric reductases duodenal cytochrome b 
(Dcytb) or stromal cell-derived receptor 2 (SDR2). Heme iron enters the cell via the 
heme carrier protein 1 (HCP1). Internalized iron enters the labile cellular iron pool of 
Fe2+. This can either be used for metabolism or can be stored as Fe3+ in ferritin in 
redox-inactive form. Ferroportin functions as iron exporter and is modulated by 
hepcidin. Exported ferrous iron will be immediately oxidized to ferric iron by the 
glycosylphosphatidylinositol (GPI)-anchored ceruloplasmin (Cp). (Modified from 
Dringen et al. 2007). 
 
 
 
Part 1  Introduction 
 
 
21 
 
Intracellular low molecular iron represents the labile iron pool which is used for the 
synthesis of heme or iron sulfur clusters (Dringen et al. 2007). However, since an 
excess of intracellular ferrous iron is cell-toxic, the amount of low molecular weight 
ferrous iron has to be tightly regulated. A safe storage for iron is the iron storage protein 
ferritin. This protein consists of 24 heavy (H) or light (L) subunits which form a 
spherical structure that accommodates about 4000 Fe atoms (Arosio et al. 2009, Arosio 
& Levi 2010). Since the H subunits of the ferritin possess ferroxidase activity, the iron 
is stored as ferric iron in a structure similar to the mineral ferrihydrite (Harrison & 
Arosio 1996, Arosio et al. 2009). The ferritin expression is regulated by the iron-
responsive protein (IRP). Low molecular weight iron incorporated in the iron-sulfur 
cluster of the IRP prevents its binding to the iron-responsive element (IRE) in the 
ferritin mRNA and thus allows the translation (Arosio et al. 2009). The upregulation of 
ferritin therefore requires the presence of intracellular low molecular weight iron. 
 
Iron is exported from cultured astrocytes by the iron exporter ferroportin (Wu et al. 
2004, Dringen et al. 2007, Garrick & Garrick 2009) which is modulated by hepcidin 
(Zechel et al. 2006, Du et al. 2011). Ferroportin is coupled to the glycosyl-
phosphatidylinositol (GPI)-anchored ceruloplasmin (Cp) which is a ferroxidase that 
oxidizes released ferrous iron to ferric iron (Patel & David 1997, Jeong & David 2003). 
 
 
1.3 Iron oxide nanoparticles and brain cells 
Several routes were discussed for NPs to enter the brain and various types of NPs have 
been considered for the delivery of drugs to the brain (reviewed in Hu & Gao 2010, 
Yang 2010). For IONPs, recent studies by Wang and colleagues showed the presence of 
IONPs in rat brain after peripheral administration, demonstrating that IONPs are able to 
cross the blood-brain barrier and to enter the brain (Wang et al. 2010). Furthermore 
fluorescent IONPs were found in the brain of mice after inhalation, suggesting that 
IONPs can also enter the brain via the olfactory neuronal pathway (Kwon et al. 2008), 
as earlier demonstrated for inhaled ultrafine carbon particles (Oberdorster et al. 2004). 
Nevertheless, data on consequences of IONPs on brain cells are rather limited so far. 
Table 1.5 summarizes the currently available studies on the consequences of a treatment 
of cultured primary brain cells with IONPs. 
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The first study on the effects of IONPs on astrocyte cultures was reported by Au and co-
workers (Au et al. 2007). Treatment of the cells with 10 µg/mL magnetic nanoparticles 
(iron oxide core, coating not specified) for 6 h did not cause any loss of membrane 
integrity but altered the mitochondrial function of the cells (Au et al. 2007). 
Furthermore, presence of IONPs inhibited adhesion of cells to the culture plate (Au et 
al. 2007). In another report, Ding and colleagues investigated the cytotoxicity of dextan-
stabilized IONPs on various cell types, including astrocyte cultures (Ding et al. 2010). 
Their study revealed that IONPs are not toxic to astrocytes even in concentrations of up 
to 500 µg/mL. Also for human astrocytes a treatment for 1 h with IONPs was not toxic 
for up to 3 d (Hadjipanayis et al. 2010). In contrast, IONPs in a concentration of 128 
µg/µL caused apoptosis in periphery blood mononuclear cells (PBMC) (Ding et al. 
2010). 
 
Uptake of IONPs by cultured astrocytes was demonstrated by TEM and fluorescence 
microscopy (Ding et al. 2010, Pickard et al. 2011). Experiments with endocytosis 
inhibitors suggest that macropinocytosis is the main mechanism of uptake of carboxyl-
modified fluorescent IONPs (0.2-0.39 µm in diameter) into astrocytes, at least in serum-
containing cell culture medium (Pickard et al. 2011). In addition, IONPs were 
successfully used for transfection of cultured astrocytes (Pickard & Chari 2010a). The 
transfection efficiency was enhanced by the application of static and oscillating 
magnetic fields while the latter effect was frequency dependent (Pickard & Chari 
2010a).  
 
In contrast to astrocytes, there is only a limited number of studies considering the 
effects of IONPs on other types of brain cells. Pickard and Chari incubated cultured 
microglial cells with commercial available carboxyl-modified fluorescent IONPs and 
observed particle uptake and concentration-dependent toxicity (Pickard & Chari 2010b). 
Jenkins et al. used another type of commercial available IONPs for gene-transfer to 
oligodendrocyte precursor cells (Jenkins et al. 2011). This transfection worked 
successfully. Its efficiency was increased by static or oscillating magnetic fields, but the 
treatment did not affect the cells ability to proliferate and to differentiate (Jenkins et al. 
2011). A very recent report by Rivet and co-workers investigated the effects of IONPs 
on cortical neurons. They demonstrated that toxicity of the IONPs strongly depends on 
Introduction  Part 1 
 
 
24 
 
their surface coating. While polydimethylamine-coated IONPs were toxic at all 
concentrations tested, aminosilane and dextran-coated IONPs had at best low effects on 
metabolic activity and membrane integrity at higher NP concentrations (Rivet et al. 
2012). 
 
Different cell-lines of neuronal origin have frequently been used as model systems to 
study the effects of IONPs on brain cells. Important results about the effects of citrate- 
and DMSA-coated IONPs were gained on the oligodendroglial cell-line OLN93 
(Hohnholt et al. 2010a, Hohnholt et al. 2011, Hohnholt & Dringen 2011). OLN93-cells 
accumulated IONPs and remained viable for up to 48 h of incubation time. The particles 
were able to provide iron for cell-proliferation under iron-restricting conditions 
(Hohnholt et al. 2010a). Furthermore, IONP-accumulation by OLN93-cells led to a 
delayed upregulation in cellular ferritin levels (Hohnholt et al. 2011) and – depending 
on the incubation conditions – also to the formation of reactive oxygen species (ROS) 
(Hohnholt & Dringen 2011). The rat pheochromocytoma cell-line PC12M is often used 
as a model system for studying neurons. Exposure of PC12-cells to DMSA-coated 
IONPs revealed particle uptake, concentration-dependent toxicity and a diminished 
capacity of the cells to extend neurites in response to nerve growth factor (NGF) 
(Pisanic et al. 2007). In contrast, Kim et al. showed recently, that PEG-encapsulated 
IONPs lead to an enhanced neurite outgrowth in PC12-cells that were exposed to both, 
IONPs and NGF (Kim et al. 2011). 
 
 
1.4 Aim of the thesis 
This thesis aims to synthesize and characterize IONPs that can be used as tools to 
investigate the uptake, reactivity and biocompatibility of IONPs on cultured astrocytes. 
A method for a reproducible synthesis of water-dispersable IONPs will be established 
based on previously published protocols (Bee et al. 1995, Geppert 2008). Of special 
interest are IONPs that are stable in commonly used biological buffer systems and 
media. This stabilization will be achieved by using proper biocompatible surface 
coatings for the IONPs, such as citrate and DMSA. The coated IONPs will be 
characterized by use of a large spectrum of physical and chemical methods. Important 
parameters that will be investigated are the size, shape and elemental composition of the 
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IONPs, the total iron content, the hydrodynamic size, surface charge and stability of 
IONPs in different buffer systems and media, and the effects of the presence of cultured 
astrocytes on the size and stability of the IONPs. 
 
Rat primary astrocyte cultures will be used as a model system to study the consequences 
of a treatment of brain cells with the synthesized IONPs. The uptake of the particles by 
viable cells will be investigated by modulating parameters such as the incubation time, 
temperature, IONP-concentration, the surface coating of the IONPs and the incubation 
medium (serum-free or serum-containing). In addition the effects of an external 
magnetic field on the particle uptake into astrocytes will be investigated. Iron uptake 
will be confirmed by measurement of the cellular iron content, by cellular staining for 
iron and by electron microscopy. Furthermore, co-incubations of cells with IONPs and 
endocytosis inhibitors will be performed to investigate an involvement of endocytotic 
mechanisms in IONP-uptake. Finally, after transient loading of the cells with IONPs, 
the long-time consequences of the presence of IONPs in astrocytes will be investigated 
by measuring several metabolic parameters like lactate export, cellular GSH/GSSG-
ratio, presence of ROS and upregulation of cellular ferritin. These investigations will 
provide experimental data on the reactivity and biocompatibility of IONPs in astrocytes 
and whether cultured astrocytes are able to liberate low molecular weight iron from 
accumulated IONPs. 
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Abstract 
Iron oxide nanoparticles (IONPs) are considered for various diagnostic and therapeutic 
applications. Such particles are able to cross the blood-brain barrier and are taken up 
into brain cells. To test whether serum components affect properties of IONPs and/or 
their uptake into brain cells, we have incubated dimercaptosuccinate-coated magnetic 
IONPs without and with fetal calf serum (FCS) and have exposed cultured brain 
astrocytes with IONPs in the absence or presence of FCS. Incubation with FCS caused a 
concentration-dependent increase in the average hydrodynamic diameter of the particles 
and of their zeta-potential. In presence of 10% FCS the diameter of the IONPs was 
increased from 57 ± 2 nm to 107 ± 6 nm and the zeta-potential of the particles from -22 
± 5 mV to -9 ± 1 mV. FCS affected also strongly the uptake of IONPs by cultured 
astrocytes. The efficient time- and temperature-dependent cellular accumulation of 
IONPs was lowered with increasing concentration of FCS by up to 90%. In addition, in 
the absence of serum, endocytosis inhibitors did not alter the IONP accumulation by 
astrocytes, while chlorpromazine or wortmannin lowered significantly the accumulation 
of IONPs in the presence of FCS, suggesting that clathrin-mediated endocytosis and 
macropinocytosis are involved in astrocytic IONP uptake from serum-containing 
medium. These data demonstrate that presence of FCS strongly affects the properties of 
IONPs as well as their accumulation by cultured brain cells. 
 
Key words:  
albumin, brain, endocytosis, fetal calf serum, IONPs 
 
Abbreviations: ANOVA, analysis of variance; BSA, bovine serum albumin, DMEM, Dulbecco’s 
modified Eagle’s medium; DMSA, dimercaptosuccinic acid; DMSO, dimethyl sulfoxide; EIPA, 5-(N-
ethyl-N-isopropyl)amiloride; FCS, fetal calf serum; HEPES, 2-(4-(2-hydroxyethyl)-1-piperazinyl)-
ethansulfonic acid; IB, incubation buffer; IONPs, iron oxide nanoparticles; LDH, lactate dehydrogenase; 
NADH, nicotinaminde adenine dinucleotide (reduced); PBS, phosphate buffered saline; SD, standard 
deviation
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1. Introduction 
Magnetic iron oxide nanoparticles (IONPs) with various types of functionalizations are 
tools for a wide range of biomedical and therapeutical applications in the brain, such as 
targeted drug delivery (Laurent et al. 2008; Yang et al. 2011; Chertok et al. 2008), 
contrast enhancement in magnetic resonance imaging (Weinstein et al. 2010; Yang 
2010), for cell labeling (Bhirde et al. 2011; Mahmoudi et al. 2011) or treatment of 
tumors via magnetic field-mediated hyperthermia (Jordan et al. 2006; Thiesen and 
Jordan 2008). Recent studies have shown, that peripherally applied IONPs are able to 
cross the blood brain barrier (Wang et al. 2010). Since astrocytes cover with their 
endfeet almost completely the brain capillaries, they have a strategically very important 
location being the first cells that encounter substances which have crossed the blood-
brain barrier (Sofroniew and Vinters 2010). In the brain, astrocytes outnumber neurons 
almost fivefold (Sofroniew and Vinters 2010) and have many important functions, 
including the supply of metabolic nutrients (Barros and Deitmer 2010), the uptake and 
release of neurotransmitters (Eulenburg and Gomeza 2010; Parpura and Zorec 2010), 
the regulation the cytosolic redox potential (Hirrlinger and Dringen 2010) and the 
regulation of iron homeostasis (Dringen et al. 2007).  
 
The stability and the aggregation behaviour of IONPs depend on the coating as well as 
on the composition of the incubation media (Chen et al. 2008; Eberbeck et al. 2010; 
Petri-Fink et al. 2008). Especially the proteins present in the fetal calf serum (FCS), 
which is a common component of culture media, interact with the nanoparticle surface 
and form a protein corona around the particles, thereby affecting their properties (Nel et 
al. 2009; Wiogo et al. 2011). The stabilization by FCS prevents precipitation of IONPs 
and allows efficient uptake of FCS-treated IONPs into some cell lines (Chen et al. 
2008).  
 
Several reports have demonstrated that cultured brain astrocytes take up IONPs both in 
the absence (Geppert et al. 2009; Geppert et al. 2011; Hohnholt et al. 2010; Lamkowsky 
et al. 2011) and in the presence (Pickard et al. 2011) of serum. For the serum condition, 
endocytotic mechanisms have been demonstrated to be involved in IONP uptake 
(Pickard et al. 2011), while inhibitors of endocytotic pathways did not lower IONP 
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accumulation in the absence of serum (Lamkowsky et al. 2011). This discrepancy 
suggests that presence of serum affects the mechanisms of IONP uptake into astrocytes.  
 
A direct comparison of IONP accumulation by brain cells in absence or presence of 
serum as well as a detailed study on the consequences of the presence of serum on 
properties of IONPs have to our knowledge not been reported so far. Therefore, we 
have addressed such questions by investigating properties of dimercaptosuccinate 
(DMSA)-coated IONPs as well as their accumulation by cultured astrocytes in the 
absence or the presence of FCS. Here we report that presence of FCS strongly increases 
the size and the zeta-potential of IONPs and severely lowers the accumulation of the 
particles by cultured astrocytes. In addition, we demonstrate that endocytosis inhibitors 
lower IONP accumulation only in the presence of serum, but not in serum-free 
conditions. These data demonstrate that properties of IONPs as well as the extent of 
IONP accumulation by astrocytes and its mechanism depend strongly on the absence or 
presence of serum components. These results should be considered for experimental and 
biomedical applications of IONPs. 
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2. Materials and Methods 
2.1 Materials 
Penicillin/streptomycin solution was obtained from Biochrom (Berlin, Germany). 
Dulbecco’s modified Eagle´s medium (DMEM) was from Gibco (Karlsruhe, Germany). 
Bovine serum albumin (BSA) and NADH were purchased from Applichem (Darmstadt, 
Germany). All other chemicals of the highest purity available were from Sigma 
(Steinheim, Germany), Fluka (Buchs, Switzerland), Merck (Darmstadt, Germany) or 
Riedel-de Haen (Seelze, Germany). 96-well microtiter plates were from Nunc 
(Wiesbaden, Germany) and 24-well cell culture plates from Sarstedt (Nümbrecht, 
Germany).  
 
Magnetic iron oxide nanoparticles (IONPs) were synthesized using an earlier described 
wet chemical method that involves co-precipitation of ferrous and ferric iron in an 
alkaline environment with subsequent oxidation via nitric acid and ferric nitrate (Bee et 
al. 1995; Geppert et al. 2009). To disperse the synthesized IONPs in the incubation 
buffers used, they were coated with dimercaptosuccinic acid (DMSA) as described 
earlier (Fauconnier et al. 1997; Geppert et al. 2011). The DMSA-coated IONPs used in 
this work consist of spherical particles with a monomodal size distribution and a mean 
hydrodynamic diameter of about 60 nm (Geppert et al. 2011). The IONP concentrations 
given represent the concentrations of total iron in the dispersions and not the 
concentration of particles. 
 
Fetal calf serum (FCS) was purchased from Biochrom (Berlin, Germany). This serum 
contained 1.33 mM phosphate as stated by the supplier. Heated FCS was obtained by 
incubation of FCS for 20 min at 90°C. Protein-free FCS was obtained by filtration of 
the FCS using Spin-X
R
6 5k MWCO concentrators (Corning, Lowell, Massachusetts) for 
20 min at 4000 g which lowered the protein content from 45.0 ± 8.6 mg/mL to 0.20 ± 
0.08 mg/mL in the filtrate.  
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2.2 Determination of particle size and zeta-potential of IONPs  
The hydrodynamic diameters of IONPs were determined by dynamic light scattering 
using the Li.S.A detector (Fraunhofer IFAM, Bremen, Germany) as described earlier 
(Geppert et al. 2011). Zeta-potential of the IONPs was determined with a Delsa™Nano 
C Analyzer (Beckmann Coulter, Krefeld, Germany).  
 
 
2.3 Cell cultures and experimental incubations 
Astrocyte-rich primary cultures were prepared from the brains of newborn Wistar rats 
as described earlier (Hamprecht and Löffler 1985). 300.000 viable cells were seeded in 
1 mL culture medium (90% DMEM, 10% FCS, 1 mM pyruvate, 20 units/mL penicillin 
G and 20 µg/mL streptomycin sulphate) in wells of 24-well cell culture plates (Sarstedt, 
Nümbrecht, Germany) and the medium was changed every seventh day. For 
experiments, cultures at an age between 15 and 22 days were used.  
 
Cells in 24-well dishes were washed twice with 1 mL pre-warmed (37°C) or ice-cold 
(4°C) incubation buffer (IB: 20 mM HEPES, 145 mM NaCl, 1.8 mM CaCl2, 5.4 mM 
KCl, 1 mM MgCl2, 5 mM glucose, adjusted to pH 7.4 at the desired temperature) and 
then incubated with 1 mL IB containing 0 or 1 mM IONPs and the indicated amounts of 
FCS and/or other compounds as indicated in the figures and tables. After incubation, the 
media were collected and the cells were washed twice with 1 mL ice-cold phosphate 
buffered saline (PBS: 10 mM potassium phosphate buffer pH 7.4, containing 150 mM 
NaCl). Dry cells were stored frozen until further investigation of their iron and protein 
contents. 
 
 
2.4 Determination of cell viability, protein content and iron content 
Cell viability was assessed by measuring the extracellular activity of lactate 
dehydrogenase (LDH) as previously described (Dringen et al. 1998) with the 
modification that 30 µL of incubation buffers and/or lysates were used in the assay. 
Protein contents were determined with the Lowry method (Lowry et al. 1951) using 
bovine serum albumin as a standard. Iron was quantified using the previously published 
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ferrozine-based iron assay (Riemer et al. 2004) which was slightly modified for the 
quantification of iron from IONPs (Geppert et al. 2009). 
 
 
2.5 Presentation of data 
If not stated otherwise, all experiments were performed at least three times, the cell 
experiments on three individually prepared cultures. The data given in the figures and 
the tables represent mean values ± standard deviation (SD). Statistical analysis for two 
sets of data was performed using the t-test. Analysis between groups of data was 
performed using ANOVA with the Bonferroni post hoc test. p>0.05 was considered as 
not significant. 
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3. Results  
3.1 Effects of FCS on properties of IONPs 
The synthesized DMSA-coated IONPs used in the present study had a monomodal size 
distribution with an average hydrodynamic diameter of 57 ± 2 nm. Incubation of IONPs 
with FCS for 4 h strongly increased the diameter of the particles as indicated by the 
shift in the size distribution curve (Fig. 1a) and by the increase in average diameter (Fig. 
1b) compared to IONPs incubated without FCS. While FCS in a low concentration of 
1% increased the mean hydrodynamic particle diameter to a maximal value of 207 ± 6 
nm, higher concentrations of FCS were less efficient to increase the diameter of the 
particles (Fig. 1b). IONPs that had been incubated in presence of 10% FCS had an 
average diameter of 107 ± 6 nm (Fig. 1b). 
 
Dispersed in serum-free incubation buffer, DMSA-coated IONPs have a zeta-potential 
of -26 ± 3 mV (Geppert et al. 2011). This value was not significantly altered by 
incubation of the particles for 4 h in IB as demonstrated by the detection of a zeta-
potential of -22 ± 5 mV (Fig. 1c). However, incubation of the particles in serum-
containing IB increased the zeta-potential significantly in a concentration-dependent 
manner. While incubation with 1% FCS increased the zeta-potential already 
significantly to -12 ± 1 mV, a treatment of the particles with 10% FCS increased the 
zeta-potential further to -9 ± 1 mV (Fig. 1c). 
 
 
3.2 Presence of serum lowers the accumulation of IONPs by astrocytes 
Cultured astrocytes are known to efficiently accumulate IONPs under serum-free 
incubation conditions (Geppert et al. 2011). To test for the consequences of the presence 
of FCS on the accumulation of IONPs by cultured astrocytes, the cells were incubated 
for up to 6 h with 1 mM iron as IONPs without (control) or with 1, 3 or 10% FCS (Fig. 
2). None of these conditions caused any significant increase in extracellular LDH 
activity (Fig. 2c), indicating that the viability of the cells was not compromised under 
the conditions used. In the absence of FCS, the specific cellular iron content increased 
within 6 h from an initial value of 12 ± 4 nmol/mg protein to 1717 ± 86 nmol/mg (Fig. 
2a). This increase in specific iron content was substantially lowered, if the cells were 
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incubated with IONPs in presence of FCS, as clearly demonstrated by specific iron 
contents of 756 ± 96 (1% FCS), 439 ± 33 (3% FCS) and 234 ± 26 (10% FCS) nmol/mg 
protein that were determined after 6 h of incubation. For all these conditions a rapid 
initial increase of cellular iron was observed for the first 15 min of incubation, after 
which the iron accumulation remained almost linear for up to 6 h.  From these linear 
increases between 15 min and 6 h, iron accumulation rates were calculated (Fig. 2b). In 
absence of FCS, the cells accumulate IONPs with a rate of 215 ± 30 nmol iron/(h × mg 
protein). This accumulation rate was significantly lowered in presence of FCS by 58%, 
80% and 89% to 90 ± 6 (1% FCS), 44 ± 3 (3% FCS) and 24 ± 4 (10% FCS) nmol 
iron/(h × mg protein), respectively (Fig. 2b). 
 
To investigate the concentration-dependent effects of FCS on IONP accumulation in 
more detail, the cells were incubated for 4 h with 1 mM IONPs in presence of different 
concentrations of FCS. To discriminate between cell-associated and internalized IONPs 
these incubations were performed at 37°C and at 4°C, since IONP internalization is 
prevented during incubation at 4°C (Geppert et al. 2011). None of the incubation 
conditions used caused a loss in cell viability as indicated by the absence of any 
significant increase in extracellular LDH activity (data not shown). If cells were 
incubated with IONPs at 37°C in the absence of FCS, their cellular iron content 
increased during 4 h to 1412 ± 128 nmol/mg protein (Fig. 3a). This value was 
significantly lowered in a concentration-dependent manner by presence of FCS during 
the incubation, resulting in as little as 171 ± 4 nmol iron/mg protein after incubation of 
the cells with IONPs at 37°C with 10% FCS (Fig. 3a). Compared to the 37°C 
conditions, incubation of astrocytes with IONPs at 4°C resulted in significantly 
(p<0.05) lower cellular iron contents for both the serum and serum-free conditions (Fig. 
3a). The data obtained for cellular iron contents of cells incubated at 4°C ranged 
between 679 ± 146 nmol/mg (incubation without FCS) and  65 ± 9 nmol/mg (presence 
of 10% FCS) (Fig. 3a). The amount of cell-associated iron detected at 4°C accounted 
for all serum concentrations applied to about 40-50% of the amount of cellular iron 
determined for cells that had been incubated with IONPs at 37°C. The differences 
between the cellular iron contents obtained after incubation at 37°C and at 4°C (Fe-
values) represent the amounts of internalized IONPs (Geppert et al. 2011). These values 
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demonstrate that FCS caused a concentration-dependent decrease in the amount of 
internalized IONPs (Fig. 3b). 
 
Investigation of the concentration-dependent effect of FCS on the hydrodynamic 
particle diameter in the supernatant of cells exposed to 1 mM IONPs at 37°C (Fig. 3c) 
revealed a maximally elevated average diameter for IONP that had been incubated with 
cells in presence of around 1% FCS (Fig. 3c). In contrast, compared to the control 
condition (absence of FCS) incubation in presence of 10% FCS did not increase the 
hydrodynamic diameter of the IONPs. For both the control conditions (absence of FCS) 
as well as for the serum conditions the IONPs in the medium of cells had a substantially 
increased diameter (Fig. 3c) compared to the values obtained for respective incubations 
in the absence of cells (Fig. 1b). The average hydrodynamic diameter of IONPs in IB 
without, with 1% serum and with 10% serum increased significantly during incubation 
with cells from 57 ± 2 to 173 ± 9 nm, from 207 ± 6 to 231 ± 3 nm and from 107 ± 6 to 
140 ± 10, respectively (Figs. 1B and 3C). 
 
 
3.3 Effects of endocytosis inhibitors on the cellular IONP accumulation 
IONP exposed astrocytes contain IONPs in intracellular vesicles (Geppert et al. 2011; 
Pickard et al. 2011), suggesting that endocytotic pathways are involved in IONP uptake. 
To investigate the mechanism of the IONP uptake in absence or presence of FCS, 
cultured astrocytes were incubated for 4 h with 1 mM IONPs in the absence or the 
presence of 10% FCS and/or compounds that have been described to affect endocytotic 
pathways (Dausend et al. 2008; Greulich et al. 2011; Huth et al. 2006; Luther et al. 
2011; Pickard et al. 2011; Rejman et al. 2004) (Tab. 1). None of the conditions applied 
caused a loss in cell viability, as indicated by the absence of any significant increase in 
the extracellular LDH activity (Tab. 1). In absence of endocytosis inhibitors, the cellular 
iron contents increased within 4 h incubation in the absence and presence of 10% FCS 
to about 1300 nmol/mg and 180 nmol/mg, respectively, as expected from the data 
presented in Figs. 2 and 3. These values were significantly lowered by incubation at 4°C 
for both the serum-free and the serum condition by 50 to 70% compared to the values 
obtained for the respective 37°C conditions (Tab. 1). While during incubation with 
IONPs in the absence of serum none of the applied endocytosis inhibitors altered 
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significantly the cellular iron content, the IONP accumulation in presence of serum was 
significantly lowered by chlorpromazine and wortmannin. IONP accumulation in the 
presence of serum was not affected by 3-methyladenine, but a 20% reduction in iron 
accumulation was observed in presence of EIPA, although this alteration did not reach 
the level of significance. Compared to controls, the application of a mixture of 
chlorpromazine, wortmannin and EIPA lowered IONP accumulation by about 50% in 
presence of 10% FCS, but did not affect IONP accumulation by astrocytes incubated 
under serum-free conditions (Tab. 1). 
 
 
3.4 Effects of serum proteins on the diameter of IONPs and on their 
accumulation by astrocytes 
To elucidate whether the proteins in FCS may be responsible for the observed effects of 
FCS on properties of IONPs and on their accumulation by cells, cultured astrocytes 
were incubated for 4 h with 1 mM IONP in IB containing untreated FCS or FCS that 
had either been heated to denature proteins or had been filtered to remove proteins. 
Alternatively, to test for protein-dependent effects the cells were exposed to IONPs in 
presence of the proteins BSA or ovalbumin. None of the conditions used caused any 
loss in cell-viability as indicated by the absence of any increase in extracellular LDH 
activity (Tab. 2). Presence of protein-free FCS during the incubation of astrocytes with 
1 mM IONPs caused aggregation and precipitation of the particles as demonstrated by 
the strong increase in their hydrodynamic diameter (Tab. 2). Under this condition, the 
lowering effect of FCS on the accumulation of IONPs by astrocytes was completely 
abolished (Tab. 2). In contrast, denaturing of proteins by heating increased the particle 
diameter only to a small extent and did not prevent the inhibitory potential of FCS on 
IONP accumulation (Tab. 2). Similarly, BSA and ovalbumin, if applied in 
concentrations corresponding to the total protein content present in the 10% FCS 
condition, did not significantly alter the diameter of the particles compared to controls 
(none), but significantly lowered IONP accumulation by astrocytes, to values similar to 
those found after treatment with 10% FCS (Tab. 2).  
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Figure 1: Effects of FCS on the hydrodynamic diameter (a,b) and on the zeta-
potential (c) of IONPs. 1 mM iron as IONPs was incubated for 4 h at 37°C with IB 
containing the indicated concentrations of FCS before the hydrodynamic particle 
diameter (a,b) and the zeta-potential (c) were determined. Stars in b and c indicate the 
significance of differences between the controls (absence of FCS) and the FCS-
containing conditions with *p<0.05, **p<0.01 and ***p<0.001. 
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Figure 2: Time dependence of the iron accumulation from IONPs in cultured 
astrocytes. The cells were incubated for up to 6 h with 1 mM iron as IONPs in 
presence of the indicated concentrations of FCS. The cellular iron content (a) and the 
extracellular LDH activity after 6 h (c) were measured. The iron accumulation rates (b) 
were calculated from the almost linear increases of the cellular iron contents between 
15 min and 6 h. In b, the significance of differences of data compared to the control 
(absence of FCS) is indicated with ***p<0.001. 
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Figure 3: Serum- and temperature-dependence of the iron accumulation from 
IONPs by cultured astrocytes and of the hydrodynamic diameter of the particles. 
The cells were incubated for 4 h with 1 mM iron as IONP in IB containing the indicated 
concentrations of FCS at 37°C or at 4°C. The cellular iron content (a) was measured, b 
shows the difference of the cellular iron contents obtained after incubation of cells at 
37°C minus that at 4°C, and c gives the average hydrodynamic diameter of the IONPs 
in the supernatant. In a and b, the values obtained for all serum-treated samples were 
significantly (p<0.05) lower than those measured for the control (absence of serum). In 
a, the values obtained for all 4°C incubations were significantly lower (p<0.05) than 
those for the respective 37°C conditions. In c, the significance of differences of data 
compared to the control (absence of FCS) is indicated with *p<0.05, **p<0.01 and 
***p<0.001. 
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4. Discussion 
4.1 Alteration of IONP properties by serum  
Presence of serum causes substantial alterations of the properties of IONPs as clearly 
demonstrated by the concentration-dependent increases in the average hydrodynamic 
diameter as well as of the zeta-potential of the particles. The negative zeta-potential of 
-22 mV of DMSA-coated IONPs in serum-free IB indicates a negatively charged 
surface, as expected from the carboxyl groups of the DMSA-coat (Fauconnier et al. 
1997). The increase in zeta potential to -9 ± 1 mV in presence of FCS demonstrates a 
loss of negative charges from the surface, which is likely to be a consequence of 
adsorption of proteins on the IONP surface which form a protein corona around the 
particles (Lynch and Dawson 2008; Nel et al. 2009; Wiogo et al. 2011). DMSA forms a 
cage-like structure around IONP (Fauconnier et al. 1997; Valois et al. 2010) that is 
crosslinked by disulfide bridges and has carboxylate and thiol groups at the surface. 
Thus, in addition to electrostatic interactions between positive surface charges of serum 
proteins with the carboxylate groups of the DMSA-coat, also disulfide bridge formation 
between thiol and disulfide groups of DMSA-coat and proteins may be involved in the 
binding of a protein layer around DMSA-coated IONPs that caused the positivation of 
their zeta-potential in presence of FCS. Although already as little as 1% FCS 
substantially increased the zeta-potential of the particles, a further positivation of the 
potential was observed by increasing the FCS concentration to up to 10%, indicating 
that coverage of the particles by serum proteins was not complete in presence of low 
serum concentrations. 
 
In contrast to the continuous increase of the zeta-potential with increasing 
concentrations of FCS, the dependence of the IONP diameter on the FCS concentration 
followed a bell shaped curve that showed a maximal particle diameter in the presence of 
around 1% FCS. This behaviour is likely to be a consequence of the simultaneous 
presence of compounds in the serum-containing medium that stabilize IONPs and/or 
induce their aggregation, i.e., ions that cause particle agglomeration and proteins that 
stabilize nanoparticles (Lynch and Dawson 2008; Wiogo et al. 2011). The proteins in 
FCS have been discussed to stabilize IONPs by preventing their interactions with low 
molecular weight ions that cause aggregation and precipitation of IONPs (Wiogo et al. 
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2011). This view of a stabilizing function of serum proteins is strongly supported by the 
observation that removal of the proteins from FCS by filtration caused immediate 
aggregation of IONPs. Since incubation media contain large concentrations of salt ions, 
a given threshold amount of protein is required to stabilize the IONPs against 
aggregation, explaining that at least 4% serum is required to stabilize carboxyl-
functionalized IONPs (Wiogo et al. 2011) and that presence of 10% FCS prevented at 
least in part the increase in diameter of IONPs that was observed for the 1% FCS 
condition. This explanation is also in accord with the observation that presence of 1% 
FCS does not lead to a maximal increase in zeta-potential. Thus, with 1% FCS protein 
coverage appears not to be maximal and presence of higher amounts of serum protein 
will improve the coverage, thereby shielding the particles away from ions and at least in 
part prevent interactions between particles and aggregation. 
 
During incubation of cells with DMSA-coated IONPs both in absence and presence of 
serum, the average diameter of the particles in the incubation buffer was significantly 
increased, confirming literature data (Geppert et al. 2011; Lamkowsky et al. 2011). 
Thus, compounds released from astrocytes are likely to induce some aggregation of the 
particles. Since the average hydrodynamic diameter of serum-treated IONPs was 
significantly higher after incubation with cells compared to control incubations without 
cells, the aggregation induced by cell-derived factors appears not to be abolished by 
high serum concentrations.  
 
 
4.2 Presence of serum affects the accumulation of IONPs by cultured 
astrocytes 
Viable cultured astrocytes have the capacity to accumulate large amounts of DMSA-
coated IONPs which increases the specific cellular iron content 100fold, confirming 
literature data (Geppert et al. 2011; Lamkowsky et al. 2011). This efficient IONP 
accumulation was severely affected by the presence of FCS. Serum lowered the increase 
in cellular iron content by almost 90%, if the cells were incubated with IONPs in 
presence of 10% FCS. This observation is consistent with recent literature data, 
demonstrating that presence of serum lowered also the uptake of negatively charged 
carboxyl-modified polystyrene nanoparticles into macrophages (Lunov et al. 2011).  
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Of the various components present in serum, the proteins are most likely to be 
responsible for the lowering of IONP accumulation in astrocytes, since removal of the 
proteins from FCS abolished the FCS-mediated reduction in IONP accumulation. Since 
albumin is the predominant protein in FCS and known to bind to the surface of IONPs 
mainly by electrostatic interactions (Yang et al. 2009), this protein is highly likely to 
bind to the particle surface, thereby lowering the uptake of IONPs by astrocytes. Indeed, 
application of pure BSA also lowered astrocytic IONP accumulation by 70%, 
confirming literature data reported for HeLa cells (Wilhelm et al. 2003). It is unlikely 
that the observed FCS-induced inhibition of IONP uptake is a specific property of 
albumin, since presence of the unrelated protein ovalbumin lowered IONP accumulation 
to a similar extent. However, the mixture of proteins present in FCS appears to be even 
more efficient to lower IONP accumulation by astrocytes than an identical 
concentration of pure BSA, suggesting that other serum proteins than BSA are 
modulating IONP surface properties and cellular uptake. This is consistent with a recent 
report describing that other serum-proteins bind more strongly to the surface of IONPs 
than BSA (Wiogo et al. 2011). 
 
Potential reasons for the drastic inhibition of astrocytic IONP-uptake by FCS could be 
the altered surface charge that enables the particles to efficiently bind to cell membranes 
as well as the increased size of the particles in presence of serum. The positive or 
negative surface charge of nanoparticles is considered to play a major role in their 
interaction with cell membranes and in their cellular uptake (Chen et al. 2011; Yue et al. 
2011). For the conditions used here, the FCS-mediated lowering of the negative surface 
charge is likely to reduce the binding of IONPs to the cells, thereby slowing also their 
uptake. Indeed, both the adsorbance of IONPs to the cells, determined as cellular iron 
content after incubation at 4°C, as well as the internalization of the particles, as 
calculated as difference of the iron values determined for cells that had been exposed to 
IONPs at 37°C and at 4°C (Geppert et al. 2011), were lowered by the same factor, 
supporting the view that binding and uptake of IONPs are simultaneously lowered in 
presence of FCS.  
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Since nanoparticle size can influence their uptake into cells (Huang et al. 2010), also the 
increased size of FCS-treated IONPs could contribute to the observed reduction in 
IONP uptake in presence of serum. However, the diameter of DMSA-coated IONPs 
increased also rapidly in serum-free incubation buffer due to factors released from the 
cells (Geppert et al. 2011; Lamkowsky et al. 2011). In addition, presence of 10% FCS 
lowered the IONP accumulation by astrocytes much stronger than presence of 1% FCS, 
although the particle diameter determined for 10% FCS was only half of that of 
particles incubated with 1% FCS. Thus, the increased size of FCS-treated IONPs 
appears not to substantially contribute to the lower IONP accumulation from serum-
containing medium compared to serum-free conditions.  
 
 
4.3 Effects of endocytosis-inhibitors on IONP accumulation by cultured 
astrocytes 
After incubation of astrocytes with IONPs the particles are present in intracellular 
vesicles (Geppert et al. 2011). This suggests that IONPs are taken up into astrocytes by 
endocytotic pathways. Indeed, for serum-containing incubation conditions some 
endocytosis inhibitors lowered significantly the uptake of IONPs, confirming previous 
results on the uptake of fluorescent IONPs in serum-containing medium (Pickard et al. 
2011). The partial inhibition of IONP accumulation in serum-containing medium by 
wortmannin and chlorpromazine, which are known inhibitors for macropinocytosis and 
clathrin-mediated endocytosis (Greulich et al. 2011; Huth et al. 2006), respectively, as 
well as the additive effects observed for a mixture of different endocytosis inhibitors 
indicate that more than one endocytotic pathway is involved in IONP uptake by 
astrocytes. This view is supported also by recent results on the uptake of silver 
nanoparticles into cultured astrocytes in serum-containing medium, which appears to 
involve macropinocytosis and the endosomal pathway (Luther et al. 2011). In contrast, 
for serum-free conditions none of the endocytosis inhibitors applied here or previously 
(Lamkowsky et al. 2011) lowered astrocytic IONP accumulation. Thus, in addition to 
the known endocytotic pathways which appear to be predominately involved in the 
uptake of serum-treated IONPs in astrocytes, another quantitatively very efficient 
mechanism of uptake for IONPs appears to be present in astrocytes that mediates most 
of the uptake of IONPs in absence of serum. 
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4.4 Conclusions 
Presence of serum strongly affects the properties and the accumulation of IONPs by 
cultured astrocytes. Although protein components of serum stabilize IONPs in 
dispersion, they also increase the diameter of the particles, strongly lower the rate of 
accumulation and alter the mechanisms involved in IONP uptake. These serum effects 
highlight the importance of clearly defined experimental conditions to understand and 
predict IONP accumulation by cells. In addition, these data are of high relevance for the 
interpretation and comparison of literature data on consequences of a treatment of 
cultured cells with IONPs. For the in vivo situation, our data suggest that IONPs applied 
to the blood are likely to be strongly affected by the presence of serum components. 
Since peripherally applied IONPs can cross the blood-brain barrier (Wang et al. 2010), 
brain cells are likely to encounter IONPs that carry serum proteins which may also in 
vivo lower their uptake into brain cells. Such a scenario should be considered for the 
development of further strategies to apply IONPs to the brain or to brain cells for 
experimental or medical reasons. 
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Abstract  
To investigate the cellular consequences of a prolonged cellular presence of large 
amounts of iron oxide nanoparticles (IONPs) as well as the fate of such particles in 
brain cells, cultured primary astrocytes were loaded for 4 h with dimercaptosuccinate-
coated IONPs. Subsequently, the IONP-treated cells were incubated for up to 7 d in 
IONP-free medium and the cell viability, metabolic parameters as well as the iron 
metabolism of the cells were investigated. Despite of an up to 100-fold elevated specific 
cellular iron content, IONP-loaded cells remained viable throughout the 7 d main 
incubation and did not show any substantial alteration in glucose and glutathione 
metabolism. During the incubation the high cellular iron content of IONP-loaded 
astrocytes remained almost constant. Electron microscopy revealed that after 7 d of 
incubation most of the cellular iron was still present in IONP-filled vesicles. However, 
the transient appearance of reactive oxygen species as well as a strong increase in 
cellular levels of the iron storage protein ferritin suggest that at least some low 
molecular weight iron was liberated from the accumulated IONPs. These results 
demonstrate that even the prolonged presence of large amounts of accumulated IONPs 
does not harm astrocytes and that these cells store IONP-derived iron in ferritin. 
 
Key words: 
brain; ferritin; glutathione; iron metabolism; oxidative stress  
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1. Introduction 
Due to their small size and their magnetic properties iron oxide nanoparticles (IONPs) 
are considered for a wide range of therapeutical and biological applications, for example 
as tool for magnetic hyperthermia, as contrast agent in magnetic resonance imaging 
(MRI), for cell labelling or for targeted drug delivery [1-6]. Also for neurobiological 
applications IONPs are considered as promising tool [7, 8]. Although IONPs have been 
shown to enter the brain by either crossing the blood-brain barrier [9] or by the olfactory 
neuronal pathway [10], little is currently known on the acute or chronic consequences of 
a presence of IONPs in brain cells. IONPs which have crossed the blood-brain barrier 
will encounter astrocytes as first parenchymal brain cells, since these cells cover with 
their endfeet almost completely the brain capillaries [11]. 
 
Astrocytes are of special interest regarding the uptake and metabolism of IONPs, since 
these cells are known to take up IONPs in vivo [12, 13] and in vitro [14-18] and since 
astrocytes are considered to play an important role in the iron homeostasis of the brain 
[19]. Astrocytes are the most abundant cell type in the brain [20] and have a variety of 
important functions in brain, including the supply of metabolic nutrients to neurons and 
the protection of the brain against metal toxicity and oxidative stress [21-23].  
 
The acute consequences of an exposure of cultured astrocytes for a few hours to IONPs 
have recently been described. Primary viable astrocytes efficiently accumulate IONPs in 
a time-, concentration- and temperature-dependent manner [14-18]. Fluorescence and 
electron microscopy revealed that IONP-exposed astrocytes contain accumulated 
IONPs in intracellular vesicles, but showed also that substantial amounts of IONPs are 
attached extracellularly to the cell membrane [14-16, 18]. These observations as well as 
the reported reduction of IONP accumulation by endocytosis inhibitors [18] suggest that 
endocytotic processes are involved in the uptake of IONPs by astrocytes.  
 
In brain, IONPs applied acutely for therapeutical and analytical purposes such as cancer 
treatment via hyperthermia [5, 24] or MRI [8] remain at the sites of instillation and are 
taken up by phagocytic cells and astrocytes where they are detectable at least for up to 7 
d [12, 13]. Although molecular interactions of IONPs with cells and within cells have 
raised concerns for potential long-term effects of IONPs [25, 26] and of IONP-derived 
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iron [27, 28], the consequences of a prolonged presence of IONPs on metabolism and 
functions of brain cells have to our knowledge not been reported so far. To address such 
questions, we have loaded cultured astrocytes with IONPs and have subsequently 
monitored for a prolonged incubation of up to 7 d in IONP-free media the cell viability 
and several metabolic parameters including the iron metabolism.  
 
IONP-loaded astrocytes which contained up to 100fold elevated specific iron contents 
compared to untreated cells remained viable during 7 d of incubation and contained 
large amounts of IONPs in intracellular vesicles. However, the transient increase in the 
production of reactive oxygen species (ROS) and the strong upregulation of the iron 
storage protein ferritin suggest that some iron was released from the vesicular IONPs 
into the cytosol. The data presented here demonstrate that cultured astrocytes cope very 
well even for a prolonged time with large amounts of intracellular IONPs that had been 
accumulated during a short bolus application of IONPs. 
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2. Materials and Methods 
2.1 Materials 
Dulbecco’s modified Eagle’s medium (DMEM) was from Gibco (Karlsruhe, Germany). 
Fetal calf serum (FCS) and penicillin/streptomycin solution were obtained from 
Biochrom (Berlin, Germany). Bovine serum albumin and NADH were purchased from 
Applichem (Darmstadt, Germany). The goat anti-L-ferritin antibody and horseradish 
peroxidase-conjugated anti-goat-IgG were obtained from Dianova (Hamburg, 
Germany). All other chemicals of the highest purity available were obtained from 
Merck (Darmstadt, Germany), Sigma (Steinheim, Germany), Fluka (Buchs, 
Switzerland), or Riedel-de Haen (Seelze, Germany). 24-well cell culture plates were 
from Sarstedt (Nümbrecht, Germany), 96-well microtiter plates and 6 cm dishes from 
Nunc (Wiesbaden, Germany).  
 
 
2.2 Iron oxide nanoparticles 
Dimercaptosuccinic acid (DMSA)-coated magnetic iron oxide nanoparticles (IONPs) 
with a core-size of about 10 nm in diameter were synthesized in a wet chemical process 
and characterized as described earlier [14, 15]. Dispersed in incubation buffer (IB; 20 
mM HEPES, 145 mM NaCl, 1.8 mM CaCl2, 5.4 mM KCl, 1 mM MgCl2, 5 mM 
glucose, adjusted to pH 7.4), DMSA-coated IONPs have an average hydrodynamic 
diameter of 60 nm and a zeta-potential of -26 mV [15]. The given concentrations of 
IONPs represent the concentrations of iron in the IONP-dispersion and not the 
concentration of particles. 
 
 
2.3 Cell cultures and experimental incubation 
Astrocyte-rich primary cultures were prepared from the brains of newborn Wistar rats 
according to a published method [29]. For Western blot experiments, 3 000 000 viable 
cells were seeded in 5 mL culture medium (90% DMEM, 10% FCS, 1 mM pyruvate, 20 
U/mL penicillin G and 20 µg/mL streptomycin sulfate) in 6 cm dishes. For all other 
experiments, 300 000 viable cells were seeded in 1 mL culture medium in wells of 24-
well dishes. For electron microscopy, the cells were seeded on Aclar film (EMS, 
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Hatfield, PA, USA) in wells of 24-well dishes. Cells were cultured at 37°C in a 
humidified atmosphere with 10% CO2 in a cell incubator (Sanyo, Osaka, Japan) and the 
medium was renewed every 7
th
 day. Experimental incubations were performed on 
cultures at an age between 15 and 21 days. 
 
To load cells with IONPs, the cells were washed twice with 1 mL (24-well plates) or 5 
mL (6 cm dishes) sterile filtered pre-warmed (37°C) IB, and than loaded for 4 h at 37°C 
in a humidified atmosphere of a CO2-free incubator in 1 mL (24-well plates) or 5 mL (6 
cm dishes) IB containing IONPs in the indicated concentrations. After 4 h of IONP-
exposure, the incubation media were collected, the cells were washed twice with 1 mL 
(24-well plates) or 5 mL (6 cm dishes) culture medium and subsequently incubated in 
culture medium for further 20 h (1 d), 68 h (3 d) or 164 h (7 d). At the indicated time-
points, the incubation media were collected and the cells were washed twice with ice-
cold phosphate-buffered saline (PBS: 10 mM potassium phosphate buffer, containing 
150 mM NaCl, pH 7.4) for analysis of cellular compounds.  
 
 
2.4 Determination of cell viability and protein content 
Cell viability was assessed by determining the activity of lactate dehydrogenase (LDH) 
and the cellular accumulation of Neutral Red (NR). Cellular and extracellular LDH 
activities were determined as previously described [30] and extracellular LDH activities 
were expressed as percentage of total (cellular + extracellular) LDH activity. NR 
accumulation was measured as recently described [31] and is expressed as percent of 
the specific initial NR uptake. Cellular protein contents were determined according to 
the Lowry method [32] using bovine serum albumin as a standard. 
 
 
2.5 Determination of iron, glutathione and lactate contents 
Iron contents of cells and media samples were quantified using a ferrozine-based iron 
assay [33] which was slightly modified for the quantification of iron from IONPs [14]. 
Total cellular glutathione (GSx = amount of glutathione (GSH) plus twice the amount of 
glutathione disulfide (GSSG)) and GSSG contents were determined using the 
colorimetric Tietze method [34] which was adapted to microtiter plates [35]. For all 
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conditions investigated here, the cellular GSSG content remained in the range of the 
detection limit of the assay used. Extracellular lactate contents were measured as 
previously described [36, 37] with the modification that 5 µL of media samples were 
used for determination. 
 
 
2.6 Staining for reactive oxygen species 
Intracellular reactive oxygen species were detected by a modification of a recently 
published method [38]. Briefly, after the experimental incubation cells were washed 
twice with IB at 37°C and subsequently incubated in 0.5 mL IB containing 5 µg/mL 
dihydrorhodamine 123 for 30 min at 37°C. Subsequently, the cells were washed twice 
with IB and fixed with 4% (w/v) paraformaldehyde in 0.1 M potassium phosphate 
buffer (pH 7.2). After washing three times with PBS, the cells were analyzed for 
fluorescence using a Nikon (Düsseldorf, Germany) TS2000U microscope.  
 
 
2.7 Western blotting and transmission electron microscopy (TEM) 
The cellular content of the ferritin protein was determined by Western blotting as 
described recently [38]. Briefly, cells incubated on 6 cm dishes were scraped off and 
centrifuged for 1 min at 12 000g. The cell pellet was lysed in water and 40 µg lysate 
protein was separated on a 12.5% polyacrylamide gel and subsequently electroblotted to 
a nitrocellulose membrane. The membranes were incubated overnight at 4°C with goat 
anti-L-ferritin antibody (1:500) in TBST (10 mM Tris-HCl, 150 mM NaCl, 0.1% (w/v) 
Tween 20, pH 7.3) containing 5% (w/v) milk powder. After washing three times with 
TBST, the membrane was exposed to horseradish peroxidase-conjugated anti-goat-IgG 
(1:10 000) diluted in TBST/5% milk powder for 1 h at room temperature. The 
membranes were washed three times with TBST and protein bands were visualized by 
enhanced chemiluminescence (GE Healthcare, Buckinghamshire, UK). 
 
The intracellular presence of IONPs was investigated by transmission electron 
microscopy (TEM) as published previously [15]. After the indicated experimental 
incubation of cells grown on Aclar film, the cells were washed twice with 1 mL PBS, 
fixed with 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer pH 7.3 for 1 h at 
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room temperature, washed trice with cacodylate buffer and postfixed with 1% (w/v) 
osmium tetroxide in cacodylate buffer for 2 h at room temperature. Dehydration was 
accomplished by incubation of the cells in solutions of increasing ethanol 
concentrations (up to 100%) followed by an incubation in acetonitrile. Finally, the cells 
were embedded in the low viscosity resin (Agar Scientific, Stansted, United Kingdom) 
and sliced with a microtome (Ultracut UCT, Leica, Germany). After staining of the 
slices with uranyl acetate and lead citrate, they were analyzed using a FEI Morgagni 
electron microscope (Eindhoven, Netherlands) operated at 80 kV.  
 
 
2.8 Presentation of data 
The data given in the figures and the table represent means ± standard deviations (SD) 
of values from at least three independent experiments that were performed on 
independently prepared cultures. Figures showing cell staining and Western blots are 
from representative experiments. Statistical analysis between groups of data was carried 
out using ANOVA with the Dunnett’s post hoc test.  
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3. Results  
3.1 Loading of astrocytes with IONPs 
To load cultured astrocytes with IONPs the cultures were exposed for 4 h to IONPs in 
concentrations of up to 4 mM iron. During the loading phase, the viability of the cells 
was not compromised as indicated by the absence of any significant increase in the 
extracellular LDH activity and by the absence of any significant loss of protein (Table 
1). Also metabolic parameters such as he NR accumulation and the specific lactate 
production by the cells during exposure to IONPs for 4 h were not significantly altered, 
while the specific GSx values were lowered in a concentration-dependent manner in 
IONP-treated cells by up to 25% for cells exposed to 4 mM IONPs (Table 1). However, 
IONP-treatment did not increase the specific content of the GSH oxidation product 
GSSG in the cells (Table 1). 
 
Exposure of astrocytes for 4 h to IONPs caused a concentration-dependent significant 
increase in the total and in the specific cellular iron contents (Table 1). The specific iron 
contents increased from 18 ± 3 nmol/mg to 366 ± 90 nmol/mg, 1086 ± 101 nmol/mg 
and 1507 ± 137 nmol/mg after application of 0.25 mM, 1 mM and 4 mM iron as IONPs, 
respectively (Table 1). TEM images of cells that had been exposed for 4 h to 4 mM 
IONPs (Fig. 1) revealed that in the cells electron-dense IONPs were almost exclusively 
found in vesicles localized close to the cell membrane (Fig. 1A,B). Most of these 
vesicles were partly filled (Fig. 1B,C) and only a few were densely filled (Fig. 1C,D) 
with IONP aggregates. High magnification revealed that the size of the individual 
particles was quite regular and most of them had diameters between 8 and 14 nm (Fig. 
1D). In addition to intracellular IONPs, electron-dense particles were attached to the 
surface of the cells either as individual particles or as particle aggregates (Fig. 1A,B) 
and were found in the space between cells (Fig. 1A) or between the cell processes (Fig. 
1C). 
 
After loading astrocytes for 4 h with IONPs, the cells were washed and subsequently 
incubated for up to 7 d in IONP-free culture medium. The following result paragraphs 
compare data obtained for IONP-loaded cells with those obtained for control cells that 
had been incubated during the loading phase without IONPs.  
Results  Part 2 
 
 
128 
 
3.2 Viability of cells 
The viability of astrocytes that had been loaded with IONPs in concentrations of up to 4 
mM was not substantially compromised during the main incubation (Fig. 2). Only after 
7 d of incubation, the extracellular LDH activity was slightly but significantly elevated 
in cells treated with 1 mM or 4 mM IONPs compared to control cells (Fig. 2A). This 
was accompanied by a small but not significant increase in the total protein contents per 
well of cultures that had been treated with 1 mM or 4 mM IONPs (Fig. 2B). 
Furthermore, the ability of IONP-treated cells to accumulate NR (Fig. 2C) and to 
produce and release lactate (Fig. 2D) was not altered compared to control cells.  
 
 
3.3 IONPs and iron in cells and media 
Loading of astrocytes with 0.25 mM, 1 mM and 4 mM iron as IONPs resulted in 
specific cellular iron levels that were elevated compared to that of control cells by 20-
fold, 60-fold and 100-fold, respectively (Table 1). These cellular iron contents remained 
almost constant during the 7 d main incubation period (Fig. 3A). Compared to the initial 
values, only cells loaded with 1 mM or 4 mM IONPs showed a small but not significant 
(p>0.05) drop in the cellular iron content after the first day of incubation that was 
accompanied by a small significant (p<0.05) increase in the extracellular iron content 
(Fig. 3B). In contrast, no further alterations in cellular and extracellular iron contents 
were observed for IONP-treated cultures during incubation for more than 1 d (Fig. 
3A,B).  
 
TEM analysis of astrocytes that had been loaded with 4 mM IONPs and were 
subsequently incubated for 7 d revealed that, in contrast to cells that had been fixed 
directly after the loading with IONPs (Fig. 1), electron-dense IONPs were not 
detectable anymore extracellularly attached to the cell membrane, but were exclusively 
localized in densely packed vesicular structures (Fig. 4). The vesicular aggregates of 
IONPs had an irregular shape and contained some cell debris that was deposited 
between the particles (Fig. 4B,C). The size of the individual IONPs was regular (Fig. 
4D) and did not differ from that found for intracellular IONPs directly after loading of 
the cells with IONPs (Fig. 1D). 
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3.4 Glutathione content and ROS production 
Treatment of the cells with IONPs led to small but significant concentration-dependent 
loss in cellular GSx (Table 1). After application of culture medium to IONP-loaded 
cells, the GSx contents increased within 1 d to up to 60 nmol/mg, which was even 
higher than the initial GSx content of the cells (Fig. 3C). During longer incubation the 
specific cellular GSx contents declined to less than 30 nmol/mg during 7 d (Fig. 3C), 
but the GSx contents of the IONP-treated cultures did not differ from that of control 
cells (loading period without IONPs) (Fig. 3C). For all conditions and time points 
investigated, the specific cellular GSSG content remained lower than 2 nmol GSx/mg 
(Fig. 3D). 
 
Since cellular liberation of iron from accumulated IONPs can lead to enhanced ROS 
formation [39, 40], the occurrence of ROS was investigated for IONP-treated astrocytes 
by using the rhodamine 123 staining (Fig. 5). Control cells (loading period without 
IONPs) showed only low staining intensity for ROS during incubation of up to 7 d (Fig. 
5A-D). In contrast, a transient increase of the rhodamine 123 fluorescence signal was 
found for cells loaded with IONPs (Fig. 5E) which became even more prominent 1 d 
after exposure to the IONPs (Fig. 5F). However, 3 d or 7 d after the IONP-loading, no 
obvious difference in rhodamine 123 staining intensity was observed anymore between 
control cells (Fig. 5C,D) and cells that had been loaded with IONPs (Fig. 5G,H). 
 
 
3.5 Ferritin content of IONP-treated astrocytes 
Incubation of cultured astrocytes with low molecular weight iron induces the synthesis 
of the iron storage protein ferritin [41]. Since ferritin synthesis requires the presence of 
an excess of low molecular weight iron in cells [42], an increase in cellular ferritin 
levels in IONP-treated cells is considered as evidence that iron is liberated from 
accumulated IONPs [38]. Therefore, ferritin levels were investigated by Western 
blotting of the proteins in cell homogenates of control cells and of cells that had been 
loaded with IONPs and were subsequently incubated for up to 7 d (Fig. 6). Hardly any 
signal for ferritin was observed for untreated astrocyte cultures (0 h) and for control 
cells that had not been exposed to IONPs (Fig. 6). In contrast, a strong ferritin signal 
Results  Part 2 
 
 
130 
 
was observed for IONP-treated astrocytes already 1 d after exposure to IONPs and the 
signal was even further intensified after incubation for 3 d or 7 d (Fig. 6).  
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Figure 1: TEM images of cultured astrocytes after loading IONPs for 4 h. A: Cross 
section through the cell-monolayer shows IONPs on the cellular surface (arrows), 
between cells (curved arrow) and in cells (arrowheads). B: Image of a cell containing 
many vesicles with IONP aggregates. In some cases smaller vesicles seem to have 
fused (arrowheads). IONPs are also present on the surface of the cell membrane 
(arrows). C: Detail image of a cell containing large, almost empty and smaller densely 
packed (circle) vesicles. Note the IONPs between the cell processes of one or several 
cells (arrows). D shows the densely IONP-packed vesicles in high magnification. The 
scale bars represent 5 (A), 1 (B,C) and 0.1 (D) µm. 
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Figure 2: Effects of IONPs on cell viability and lactate production by astrocytes. 
The cells were loaded for 4 h with IONPs in the indicated (A) concentrations and then 
incubated in culture medium for up to 7 d. The extracellular LDH activity (A), the 
cellular protein content (B), the NR accumulation (C) and the lactate production (D) 
were determined. The initial values of protein content and NR accumulation are given 
in Table 1 and are indicated by the dashed lines in B and C. Stars show the 
significance of differences compared to values obtained for controls (0 mM IONPs) with 
**p<0.01. 
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Figure 3: Effects of IONPs on the contents of iron and glutathione in astrocytes. 
The cells were loaded for 4 h with IONPs in the concentrations indicated (D) and then 
incubated in culture medium for up to 7 d. The cellular iron content (A), the extracellular 
iron content (B), the cellular GSx content (C) and the cellular GSSG content (D) were 
determined. Iron values are given as nmol per well (A,B), GSx and GSSG contents as 
specific values normalized on the cellular protein content as nmol/mg. The initial value 
for the specific cellular GSx content is given in Table 1 and is indicated by the dashed 
line in C. Stars indicate the significance of differences compared to controls (0 mM 
IONPs) with *p<0.05 and **p<0.01. 
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Figure 4: TEM images of cultured astrocytes 7 d after loading with IONPs. A: 
Cross section through the cell shows that IONPs are not anymore detectable on the 
cell surface but are exclusively accumulated in intracellular vesicles. B: Astrocyte 
containing many vesicles densely filled with IONPs and some cell debris. C: Detailed 
images of a densely packed vesicle with irregular outline (circle). D: High resolution 
image of the IONPs inside the vesicles. The scale bars represent 5 (A, B), 1 (C) and 
0.1 (D) µm. 
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Figure 5: ROS-staining of cultured astrocytes after exposure to IONPs. The cells 
were loaded for 4 h without (control) or with 4 mM IONPs and then further incubated 
without IONPs in culture medium for up to 7 d. 
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Figure 6: Western blot for the iron storage protein ferritin. The cells were loaded 
for 4 h without (control) or with 4 mM IONPs and then incubated without IONPs in 
culture medium for up to 7 d. Cell lysates containing 40 µg protein were loaded to each 
lane, separated by electrophoresis and analyzed for ferritin content by Western 
blotting. 
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4. Discussion 
To investigate long-time consequences of a short exposure of cultured astrocytes to 
IONPs, the cells were loaded for 4 h with DMSA-coated IONPs. This treatment 
increased the specific cellular iron content by up to 100-fold, but did not compromise 
cell viability. Also basal metabolic parameters such as the accumulation of NR and the 
production of lactate by the cells were not altered during exposure to IONPs, 
demonstrating a remarkable resistance of cultured astrocytes towards any acute toxicity 
of IONPs. TEM revealed that a substantial amount of cell-associated IONPs had been 
taken up into the cells within the 4 h loading period but that another part of the IONPs 
were attached extracellularly to the cells. These data are consistent with the recently 
reported membrane adsorption and efficient internalization of IONPs by viable cultured 
astrocytes [15, 17].  
 
Treatment of cultured astrocytes with 1 mM or 4 mM IONPs caused a small but 
significant reduction in cellular GSH contents, as previously reported also for MRC-5 
cells [43] and OLN-93 cells [40] and. This loss of up to 25% of the cellular GSH after 
IONP-treatment of astrocytes is likely to be mediated by conjugation of GSH to the 
DMSA-coat of the IONPs, since only DMSA-coated IONPs, but not citrate-coated 
IONPs, lower the GSH content of OLN-93 cells [40]. The ability of DMSA-coated 
IONPs to directly react with GSH is also supported by the disappearance of detectable 
GSH, but not of GSSG, in cell-free incubations with DMSA-IONPs (data not shown), 
strongly suggesting that the thiol group of GSH reacts with the disulfide bridges that 
stabilize the DMSA-coat [44, 45] of the IONPs used in our study. The small loss in 
cellular GSH levels after IONP-loading of astrocytes was fully compensated by 
synthesis of GSH during a subsequent incubation in the amino acid-containing culture 
medium, demonstrating that cellular presence of IONPs does not prevent GSH 
synthesis.  
 
Presence of up to a 100-fold elevated cellular iron content of IONP-treated astrocytes 
did not compromise cell viability during a subsequent prolonged incubation for up to 7 
d, as indicated by the low activity of extracellular LDH and by the absence of any loss 
in cellular protein. Also cellular processes such as NR accumulation or glycolytic 
Part 2  Results 
 
 
139 
 
lactate production were not altered in IONP-containing cells, contrasting for example 
the situation reported for astrocytes that were treated with copper [31].  
 
Exposure of cultured astrocytes to IONPs induced ROS formation in astrocytes, as 
recently reported for other types of neural cells [40, 46]. The generation of ROS is 
likely to be a result of the iron-catalyzed Fenton reaction, which can either occur on the 
surface of IONPs [25, 47] or is catalyzed by iron liberated from accumulated IONPs 
[27]. The elevated ROS production in IONP-treated astrocytes was transient and most 
prominent 1 d after IONP-loading, but completely disappeared after incubation for 3 d 
or 7 d. A likely reason for this observation is the strong upregulation of ferritin 
synthesis in IONP-loaded astrocytes, which will sequester IONP-derived low molecular 
weight iron and store it in redox-inactive form, thereby preventing iron-mediated ROS 
formation [41]. Despite of the transient elevated ROS production, the viability of IONP-
containing astrocytes was not substantially compromised nor were cellular GSSG levels 
increased, suggesting that IONP-treated astrocytes do not suffer from severe oxidative 
stress. This contrasts the situation of astrocytes that encounter oxidative stress due to the 
presence of metal ions or hydrogen peroxide [41, 48-50].  
 
The high resistance of astrocytes against IONP-mediated toxicity, contrasts literature 
reports that show severe toxicity of MRC-5 lung fibroblasts [43] or PC12 cells [51] 
after exposure to IONPs. However, a high resistance against metal- and nanoparticle-
induced toxicity [15, 50, 52, 53] appears to be a special feature of astrocytes that is 
consistent with the proposed function of this cell type as regulator of metal metabolism 
in brain [19, 23]. Molecular mechanisms that could contribute to a high resistance of 
astrocytes against metal- and nanoparticle-induced toxicity include the upregulation of 
metal storage and binding proteins such as ferritin [41, 54] or metallothioneins [55, 56] 
and the endocytotic uptake of nanoparticles into vesicular compartments [15, 18, 53].  
 
After loading of cultured astrocytes with IONPs, the cellular iron content remained 
almost constant. Only during the first day of incubation a low increase in the amounts of 
extracellular iron was found for cells treated with high concentrations of IONPs, which 
may be the consequence of desorption of some of the membrane-adsorbed IONPs that 
were visible in the TEM pictures of IONP-treated cultures after 4 h. Membrane-
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adsorbed IONPs represent around 50% of the cell-associated iron determined directly 
after loading of astrocytes with IONPs [15], but the total cellular (internalised and 
membrane-attached) iron content was only lowered by around 10% during the first day 
of incubation and remained constant during further incubation. Cell-attached electron-
dense material was not detected anymore after 7 d of incubation, suggesting that the 
majority of the membrane-associated IONPs observed by TEM for acutely loaded 
astrocytes had been internalized. After 7 d of incubation the cellular IONPs were 
densely packed in large vesicles, but no obvious alteration in the size of the individual 
particles was found. Some of the IONP-containing vesicles observed in the cells may be 
lysosomes, since the low pH of these organelles has been discussed to contribute to the 
liberation of iron from accumulated IONPs [27].  
 
The presence of large IONP aggregates in astrocytes 7 d after exposure to the particles 
suggests that a large part of the accumulated IONPs remain deposited as electron-dense 
IONP-aggregates in cellular vesicles. However, the upregulation of ferritin in IONP-
treated astrocytes demonstrates that some iron was liberated from the accumulated 
IONPs into the cytosol, since this processes requires the presence of low molecular 
weight iron [38, 40, 42, 57]. The relative stability of IONP-aggregates in vesicles as 
well as the strong upregulation of ferritin are likely reasons for the high resistance of 
astrocytes against potential IONP-toxicity. Slow release of iron from accumulated 
IONPs as well as effective storage of IONP-derived iron in ferritin explains also the 
absence of any substantial iron release from IONP-containing astrocytes during 
prolonged incubation, although this cell type is known to have the capacity to release 
low molecular weight iron [58]. 
 
 
5. Conclusions 
The data presented demonstrate that the presence of large iron contents in astrocytes 
that had been exposed for a short time to IONPs does not compromise cell viability and 
metabolism during a subsequent prolonged incubation. Although IONPs were found 
densely packed in intracellular vesicles after 7 d of incubation, some iron was also 
liberated from the accumulated IONPs, at least in amounts that induced a strong 
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upregulation of ferritin in astrocytes. These data suggest that vesicular deposition of 
accumulated IONPs as well as efficient storage of IONP-derived low molecular weight 
iron in ferritin contribute to the resistance of astrocytes against potential toxicity of 
IONP-derived iron. Such processes are likely to enable also astrocytes in brain, which 
are known to take up IONPs after a bolus application for therapeutical or diagnostic 
reason [12, 13], to deal successfully with accumulated IONPs and with its iron content 
for a prolonged time. 
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3. Summarizing discussion 
Magnetic iron oxide nanoparticles (IONPs) are considered for a wide range of 
therapeutical and diagnostic applications in the brain (Yang 2010, Winer et al. 2011, 
Yigit et al. 2012). Such particles are able to cross the blood-brain barrier (Wang et al. 
2010) or can enter the brain via the olfactory neuronal pathway (Kwon et al. 2008). 
IONPs which have been injected into the brain are taken up by macrophages and 
astrocytes and remain at the site of injection for at least 7 d (Murillo et al. 2005, van 
Landeghem et al. 2009). However, data about the effects of IONPs on brain cells are 
limited so far. 
 
This thesis investigated the effects of IONPs on cultured brain astrocytes as a model 
system for astrocytes in the brain. Viable cultured astrocytes accumulated large amounts 
of citrate- or dimercaptosuccinate (DMSA)-coated IONPs and stored them in 
intracellular vesicles. The uptake rates of IONPs depended strongly on the experimental 
incubation conditions, such as time, temperature, IONP-concentration, composition of 
the incubation medium and the presence of external magnetic fields.  For none of the 
conditions investigated, the presence of extracellular or intracellular IONPs 
compromised cell viability or altered metabolic parameters. However, a transient 
formation of reactive oxygen species (ROS) and a strong upregulation of the iron 
storage protein ferritin suggest that low molecular weight iron is liberated in astrocytes 
from accumulated IONPs. 
 
 
3.1 Iron oxide nanoparticles 
3.1.1 Synthesis and coating 
IONPs were synthesized according to a previously published method (Bee et al. 1995) 
which was slightly modified (Geppert 2008). The resulting magnetic fluid contained 
polydisperse IONPs with a mean diameter of 8 nm as observed by transmission electron 
microscopy (TEM), which is consistent with literature data (Bee et al. 1995). The used 
synthesis method for IONPs showed a good reproducibility regarding size, shape and 
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the iron content of the resulting IONP-dispersions. In a total number of nine 
experiments, the average yield of the synthesis was 71 ± 12% regarding the total iron 
content of the dispersion. 
 
IONPs were coated either with citric acid or with DMSA to stabilize them in the 
incubation buffers used for cell-experiments. Both compounds have been described in 
the literature as suitable for stabilization of IONPs in biological media (Fauconnier et 
al. 1997, Racuciu et al. 2006). Since citrate-coated IONPs were only stable in 
incubation buffer in presence of a high excess of citrate (Publications 1 and 2) which at 
least in millimolar concentrations is likely to affect cellular functions (Westergaard et 
al. 1994), the majority of the studies of this thesis were undertaken using DMSA-coated 
IONPs. These IONPs were extensively characterized regarding their core-size, 
elemental composition, hydrodynamic size distribution and surface charge. 
 
 
3.1.2 Characterization 
DMSA-coated IONPs contain a core of iron oxide which is surrounded by a shell of 
DMSA molecules that are cross-linked via disulfide bridges and thus form a cage-like 
structure around the core (Fauconnier et al. 1997, Valois et al. 2010). The presence of 
the DMSA-coating of the here used IONPs was confirmed by the detection of sulfur via 
energy dispersive X-ray spectroscopy (EDX), since DMSA was the only sulfur-
containing compound present during the IONP-preparation (Publication 3). 
 
Dispersed in water, uncoated IONPs as well as citrate- or DMSA-coated IONPs had an 
average hydrodynamic diameter of about 60 nm as determined by dynamic light 
scattering (DLS). This large increase in particle size compared to the results obtained by 
TEM demonstrates that the IONPs form small agglomerates in dispersion probably due 
to magnetostatic interactions (Chantrell et al. 1982, Maity & Agrawal 2007). 
 
The uncoated IONPs dispersed in water had an acidic pH-value and a positive zeta-
potential as expected due to their positive surface charge that is caused by protonated 
hydroxyl groups at the surface of IONPs (Cheng et al. 2005). Thus, IONPs are 
stabilized in water by electrostatic repulsive forces between equally charges particles 
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(Laurent et al. 2008). After dispersion in incubation buffer at a physiological pH-value, 
the surface hydroxyl groups are deprotonated and thus loose their positive charges. 
These uncharged particles are not electrostatically stabilized anymore and rapidly 
aggregate and precipitate at physiological pH. In contrast, DMSA-coated IONPs have a 
negative zeta-potential at physiological pH due to the negatively charged carboxylate 
groups of the coating material, thereby maintaining the stabilization via electrostatic 
repulsive forces and keeping the particles dispersed in physiological incubation buffers. 
 
Fetal calf serum (FCS) is often added as supplement for cell culture media and has been 
described to stabilize IONPs (Wiogo et al. 2011). However, presence of 10% FCS or 
other proteins such as bovine serum albumin (BSA) or ovalbumin in the incubation 
buffer lead to a 2-3 fold increase of the hydrodynamic diameter of dispersed DMSA-
coated IONPs and to a positivation of their zeta-potential. This can be explained by 
binding of such proteins to the IONP surface forming a protein-corona as previously 
described (Lynch & Dawson 2008, Nel et al. 2009, Wiogo et al. 2011). A similar 
increase of the hydrodynamic IONP-diameter was observed for IONPs after incubation 
with cultured astrocytes in incubation buffer (Publication 3) or in astrocyte 
preconditioned medium (Chatterjee 2011). This effect was concentration dependent 
(stronger increase in IONP-size at lower IONP-concentrations) but independent of the 
presence or absence of FCS in the incubation buffer (Publication 3; 
Publication/Manuscript 5). These observations suggest that substances released by the 
astrocytes into the medium are causing IONP-agglomeration. Indeed, serine protease 
40, a protein that is released from cultured astrocytes, has been identified to be bound 
on the IONP surface (Chatterjee 2011). 
 
 
3.2 Uptake and biocompatibility of iron oxide nanoparticles in 
cultured astrocytes 
Citrate- and DMSA-coated IONPs were used to study the uptake and biocompatibility 
of IONPs in cultured astrocytes. However, since DMSA seemed to be the better surface 
coating-material as it allowed to obtain stable IONPs in the absence of any free coating-
material, only initial studies were performed for citrate-coated IONPs and most of the 
studies were carried out with DMSA-coated IONPs. Uptake of IONPs was quantified by 
Part 3  Summarizing discussion 
 
 
151 
 
measuring the total cellular iron content and visualized by Perl’s staining and electron 
microscopy. Acute effects of IONPs on cultured astrocytes were studied during an 
exposure of the cells to IONPs for up to 6 h. In addition, long term consequences of the 
cellular presence of IONPs were investigated for up to 7 d after loading of the cells for 
4 h with IONPs. 
 
 
3.2.1 Quantification of the iron accumulation 
Only very recently was demonstrated that cultured astrocytes are able to take up IONPs 
(Ding et al. 2010, Pickard & Chari 2010, Pickard et al. 2011, Yiu et al. 2011). 
However, the first detailed quantitative analysis of the iron accumulation by cultured 
astrocytes from IONPs is provided by the publications and manuscripts of the present 
thesis. Details are given in the individual chapters of this thesis. A summary on the 
consequences of alterations of experimental incubation parameters on the cellular iron 
accumulation is given in Table 3.1. 
 
 
Table 3.1: Modulation of the accumulation of IONPs in cultured astrocytes 
Changed experimental parameter 
Cellular iron content 
n 
(nmol/mg) (% of control) 
Control (4 h, 1 mM DMSA-IONPs, 37°C) 1375 ±   260 100 ± 19 28 
Elongation of incubation time to 6 h 2151 ±   198 156 ± 14   6 
Increase of IONP concentration to 4 mM 2209 ±   385 161 ± 28 10 
Lowering incubation temperature to 4°C   726 ±   214   53 ± 16 19 
Addition of 10% FCS   182 ±     24   13 ±   2   9 
Application of an external magnetic field 4411 ± 1062 321 ± 77   6 
Use of citrate-coated IONPs 1507 ±   142 110 ± 10   6 
The table shows how the indicated alterations of the experimental conditions affect the 
cellular iron content of IONP-exposed astrocytes. Basis for the calculation are the data 
given in the publications/manuscripts in the chapters 2.2 to 2.6 of this thesis. Iron 
contents were given as specific values normalized on the cellular protein content and 
as percentage of the control. A 4 h incubation of astrocytes with 1 mM DMSA-coated 
IONPs at 37°C is defined as control condition. 
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Cultured astrocytes effectively accumulated both, citrate- and DMSA-coated IONPs as 
shown by a strong increase in the cellular iron content exceeding the initial iron content 
by more than 100-fold. The cellular iron contents of IONP-treated astrocytes were even 
five to ten times higher than the cellular iron contents resulting from incubation with 
low molecular weight ferric ammonium citrate (FAC) (Hoepken et al. 2004, Riemer et 
al. 2004, Tulpule et al. 2010, Bishop et al. 2011). However, for none of the conditions 
applied, any acute loss in cell viability was observed, indicating that astrocytes are 
remarkably resistant to IONPs and are able to safely store these large amounts of 
accumulated iron. 
 
The accumulation of citrate-coated IONPs did not significantly differ to the 
accumulation of DMSA-coated IONPs by astrocytes under otherwise identical 
experimental conditions. This was expected since both types of IONPs have almost 
identical core sizes, hydrodynamic diameters and negative surface charges (Publications 
2, 3) (Bee et al. 1995, Fauconnier et al. 1997). TEM revealed that this increase in iron 
content of IONP-treated astrocytes is a result of uptake and membrane association of 
IONPs or IONP-aggregates (Publication 3). Lowering the incubation temperature to 4°C 
lowered the iron accumulation to around 50% of the amount obtained at 37°C. For the 
4°C condition, only extracellular membrane bound IONPs/IONP-aggregates were 
observed by TEM (Publication 3), as expected, since membrane transport processes are 
strongly reduced at 4°C (Kim et al. 2006, Wilhelm & Gazeau 2008). Thus, Fe-values 
that represent the difference between cellular iron contents obtained at 37°C and 4°C 
give the amount of iron internalized due to IONP-uptake. It should be kept in mind that 
the Fe represents only about 50% of the iron content observed at 37°C for all 
experiments performed to investigate IONP-accumulation. The second half of the 
specific iron content represents extracellularly adsorbed IONPs. 
 
In addition to a temperature dependency, IONP-accumulation was time and 
concentration dependent. Over time, no maximal IONP-accumulation was observed for 
the conditions investigated in this thesis. However, cellular iron contents were only 
determined for up to 6 h incubation of astrocytes with IONPs, since long incubations of 
the cells with IONPs in incubation buffer for 24 h compromise cell viability (data not 
shown). The concentration dependency of IONP-accumulation showed a saturation in 
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IONP-uptake for high concentrations. This saturation was observed for incubations at 
37°C and 4°C, indicating that IONP-uptake and membrane association are saturable 
processes. Analysis of the IONP internalization (Fe-values) after 4 h for DMSA-
IONP-concentrations of up to 4 mM revealed a Michaelis-Menten like kinetic with 
apparent KM- and Vmax-values of 2.1 ± 0.6 mM and 1871 ± 231 nmol iron/(mg × 4 h), 
respectively (Publication 3). This represents the first description of kinetic parameters 
of IONP-uptake into cells. 
 
IONP-uptake was strongly enhanced in the presence of an external magnetic field that 
was generated by positioning NdFeB-magnets underneath the cells. The observed 
cellular iron contents at 37°C and 4°C increased by about 3-fold compared to the 
respective conditions without magnets, demonstrating that both the IONP-
internalization and the membrane association of IONPs were increased due to the 
magnetic field. This leads to even more cellular iron than expected from the saturation 
found in the concentration dependency of IONP-accumulation by astrocytes. Potential 
reason for this observation could be the formation and accumulation of larger IONP-
aggregates in the magnetic field (Chantrell et al. 1982). Such an increase in IONP-
accumulation was previously described for various cell lines (Petri-Fink & Hofmann 
2007, Prijic et al. 2010) and also for magnetic-nanoparticle mediated gene-transfer in 
astrocytes (Pickard & Chari 2010). However, a detailed time-, concentration- and 
temperature-dependent analysis of magnetic-field induced IONP-uptake in astrocytes 
was first described in the context of this thesis (Publication 4). 
 
Presence of FCS in the incubation buffer led to a strong reduction in IONP-uptake in 
cultured astrocytes. Proteins of FCS are likely to bind to the surface of the IONPs 
(Wiogo et al. 2011) forming a so-called protein corona (Nel et al. 2009) around DMSA-
IONPs. This results in an increase in particle size and in a positivation of their zeta-
potential (Publication/Manuscript 5) which is likely to influence the interactions 
between the IONPs and the cell membranes and subsequently results in reduction in 
IONP-uptake. The strong effect of presence of serum or other proteins on IONP-uptake 
into brain cells was shown for the first time in this thesis. However, effects of serum on 
the uptake of different types of IONPs by various cell lines have been previously 
reported. Depending on the cell-type, the medium and the type of IONPs used, presence 
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of serum either decreased or increased IONP-uptake (Chen et al. 2008, Petri-Fink et al. 
2008). 
 
 
3.2.2 Mechanisms of particle uptake 
IONPs which have been taken up by astrocytes were found to be incorporated in 
intracellular vesicles as shown by TEM (Publications 2,3). This strongly suggests the 
involvement of endocytotic pathways in IONP-uptake. Astrocytes in culture are known 
to have an active endocytotic system and to express proteins involved in different 
endocytotic pathways (Megias et al. 2000). However, because of the large number of 
different endocytotic pathways (Kumari et al. 2010, Platta & Stenmark 2011, Sandvig et 
al. 2011) the identification of the pathways involved in IONP-uptake in cultured 
astrocytes is quite complicated. In this context, it has to be noted that the specificity of 
substances that have been described to modulate and inhibit these pathways (Rejman et 
al. 2004, Huth et al. 2006, Dausend et al. 2008, Greulich et al. 2011, Luther et al. 2011, 
Pickard et al. 2011) is a matter of debate (Ivanov 2008). 
 
For serum-containing conditions, macropinocytosis and clathrin-mediated endocytosis 
appear to contribute to IONP-uptake into cultured astrocytes (Publication/Manuscript 5; 
Figure 3.1). This confirms data reported by Pickard and colleagues who incubated 
astrocytes with larger (0.20-0.39 µm) carboxyl-modified fluorescent IONPs (Pickard et 
al. 2011). However, macropinocytosis and clathrin-mediated endocytosis seem not to be 
the only pathways involved in IONP-uptake in astrocytes since the Fe-values of the 
inhibitory conditions are still higher than the 4°C control which represents extracellular 
bound IONPs. In contrast, for serum-free conditions none of the inhibitors applied lead 
to a significant reduction in cellular iron content of IONP-treated astrocytes (Publication 
4; Publication/Manuscript 5) suggesting that especially IONPs coated by serum-proteins 
but not DMSA-IONPs are taken up by macropinocytosis and clathrin-mediated 
endocytosis into astrocytes. Since incubation of cultured astrocytes with DMSA-IONPs 
in serum-free buffer lead to an about 8 times higher cellular iron content, a highly 
effective pathway has to be responsible for IONP-uptake under serum-free conditions 
which remains to be identified. Figure 3.1 shows the mechanisms which may be 
responsible for IONP-uptake in cultured astrocytes. 
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Figure 3.1: Mechanisms of IONP-uptake into cultured astrocytes. Substantial 
amounts of IONPs will attach extracellularly to the cell membrane. Cultured astrocytes 
take up IONPs in serum containing medium by macropinocytosis and by clathrin-
mediated endocytosis. In addition, another unknown pathway is likely to be involved in 
particle uptake. For serum-free conditions, the uptake-mechanism could not be 
identified so far. 
 
 
3.2.3 Consequences of a prolonged presence of particles 
IONPs, which are applied for diagnostic or therapeutic reasons into the brain will be 
accumulated by macrophages and astrocytes and remain there for at least 7 d (Murillo et 
al. 2005, van Landeghem et al. 2009). However, data about the long term consequences 
of the presence of IONPs in brain cells have not been reported so far. This thesis 
presents an analysis of the metabolic effects of a prolonged presence of large amounts 
of IONPs following a bolus application to cultured astrocytes. This experimental 
paradigm is considered as a model-system for studying the consequences of cellular 
presence of IONPs and for the fate of IONPs in brain cells. 
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The experimental setup composed of a 4 h loading phase of astrocytes with up to 4 mM 
IONPs in incubation buffer and a subsequent up to 7 d main incubation in culture 
medium. These conditions did neither compromise the cell viability, nor affect 
glycolytic lactate production or the cellular glutathione/glutathione disulfide 
(GSH/GSSG)-ratio (Publication/Manuscript 6). Only a slight decrease of cellular GSx 
after the loading phase was observed, which is a likely result of conjugate formation 
between GSH and the DMSA-coating since citrate-coated IONPs did not cause such an 
effect (Hohnholt & Dringen 2011). A summary of the pathways involved in handling of 
intracellular IONPs by astrocytes is given in Figure 3.2. 
 
 
Figure 3.2: Cellular fate considered for IONPs in cultured astrocytes. After uptake, 
the nanoparticles may be directed to the lysosomes. Due to the acidic pH low 
molecular weight iron is liberated from the IONPs which is than exported into the 
cytosol via the divalent metal transporter 1 (DMT1). Here it enters the labile iron pool 
and can either induce the formation of hydroxyl radicals, be stored as ferric iron in 
ferritin or be incorporated in iron containing proteins. 
 
 
After the 4 h loading-phase of cultured astrocytes with IONPs, a large amount of 
cellular IONPs was decorating the cell membrane, while 7 d after the loading IONPs 
were exclusively detected in intracellular vesicles (Publication/Manuscript 6). This 
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suggests that membrane associated IONPs were incorporated during this time frame. A 
significant export of iron or IONPs was not detectable during 7 d, underlining the role 
of astrocytes to function as metal depots (Tiffany-Castiglioni & Qian 2001, Dringen et 
al. 2007, Tiffany-Castiglioni et al. 2011). IONPs and/or their containing iron seemed to 
be stored safely in the astrocytes even though it is known, that cultured astrocytes 
express the iron exporter ferroportin (Wu et al. 2004, Dringen et al. 2007, Garrick & 
Garrick 2009). 
 
Presence of IONPs led to a transient formation of ROS and to a delayed upregulation of 
the iron storage protein ferritin in cultured astrocytes. While ROS are likely to be 
generated by the Fenton reaction either on the surface of IONPs (Voinov et al. 2011) or 
due to the liberation of low molecular weight ferrous iron from the particles (Levy et al. 
2010), ferritin upregulation requires intracellular low molecular iron (Arosio et al. 
2009). Therefore, at least the upregulation of ferritin indicates liberation of low 
molecular weight iron from the IONPs in the cells. Such a liberation may occur in the 
lysosomes since their acidic pH is likely to foster IONP-degradation (Levy et al. 2010). 
Ferrous iron is than exported into the cytosol via the divalent metal transporter 1 
(DMT1) which is expressed in cultured astrocytes (Burdo et al. 2001, Tulpule et al. 
2010), where it is entering the labile iron pool. Here it can be stored in ferritin (as ferric 
iron), induce ROS-generation or it can even be used for cell metabolism, for example 
for proliferation as recently published for OLN93-cells (Hohnholt et al. 2010, Hohnholt 
et al. 2011). Nevertheless, it has to be mentioned that for the time frame investigated 
only a small amount of the total internalized particles appears to have been degraded to 
low molecular weight iron, since TEM-pictures showed vesicles densely packed with 
IONPs 7 days after loading. Furthermore, a complete dissolution of the IONPs uptaken 
by the cells would lead to an intracellular iron concentration of 526 ± 92 mM (4 h 
incubation with 4 mM IONPs at 37°C), which would rapidly induce osmotic cell death. 
 
 
3.3 Conclusions and future perspectives 
This thesis investigated the synthesis and characterization of citrate- and DMSA-coated 
IONPs as tools for studying uptake, reactivity and biocompatibility of IONPs in brain 
cells. The cells in astrocyte-rich primary cultures efficiently took up citrate- and 
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DMSA-coated IONPs without any acute loss in their viability. Even prolonged presence 
of IONPs in the cells did neither compromise cell viability nor substantially alter 
cellular metabolism. However, a transient formation of ROS and a strong upregulation 
of ferritin indicate liberation of low molecular weight iron from accumulated IONPs. In 
summary, the results of this thesis suggest that IONPs at least for the conditions 
investigated can be considered as save tool for biomedical and clinical applications and 
could even be a useful and safe iron source. 
 
IONPs were taken up and stored in intracellular vesicles. In further studies, a detailed 
analysis of the subcellular localization of the particles in cells should be done. Such 
questions could be addressed by fractioning of cells via differential and density gradient 
centrifugation (Aronson & Touster 1974, Ozols 1990, Tedelind et al. 2010) after 
incubation with IONPs and quantifying the iron content of the different fractions. 
However, it has been shown that such a cell-fractionation is complicated due to the high 
density of the IONPs (Petters 2010). More detailed information about the subcellular 
fate of the IONPs could be gained by immunogold labeling of the vesicles combined 
with electron microscopy (Mayhew 2011). Furthermore, the use of fluorescent IONPs 
will simplify studying the intracellular fate of such particles. DMSA-coated fluorescent 
IONPs were successfully synthesized (Kaltz 2011) and at least are taken up by cultured 
OLN93-cells (Bulcke 2012). 
 
The mechanism of IONP-uptake – especially under serum-free conditions – is another 
unsolved aspect of this thesis. Additional experiments with other types of endocytosis 
inhibitors under varying experimental conditions could help to reveal these yet 
unknown pathways. A potential reason for the unclear results of the inhibitor studies 
could be that the large size distributions of the IONP-dispersions address several 
endocytotic mechanisms. These may contribute together to the IONP-uptake, since it is 
known that endocytotic uptake mechanisms strongly depend on the particle size 
(Rejman et al. 2004). In addition, the use of fluorescently labeled IONPs could help to 
address the unsolved questions for the IONP-uptake mechanism(s). 
 
IONPs accumulated by cultured astrocytes liberate iron which is intracellularly stored in 
ferritin as shown by Western Blotting. However, ferritin molecules were not detected 
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via TEM. Such an electron microscopic detection of ferritin has been shown (Lopez-
Castro et al. 2011) and could be an additional prove for the release of low molecular 
weight iron from the IONPs in astrocytes. Furthermore, immunocytochemical detection 
of cellular ferritin could be undertaken in future. A better quantification of the ratio of 
intracellular IONPs, low molecular weight iron and ferritin will be an important task for 
further studies. One method to quantify intracellular low molecular weight iron could be 
the use of fluorescent dyes like Phen Green
TM
 or calcein (Kakhlon & Cabantchik 2002, 
Petrat et al. 2002). 
 
The purity of the used cultures is another important task that should be considered for 
future studies. The here used astrocyte-rich primary cultures contain mainly, but not 
exclusively, astrocytes. Small amounts of oligodendrocyte precursor cells, ependymal 
and microglia cells which are present in these cultures (Reinhart et al. 1990, Gutterer et 
al. 1999, Dang et al. 2010) are able to also contribute to the observed IONP-uptake. The 
use of secondary cultures could be a possibility to obtain purer astrocyte-cultures that 
hardly contain any other type of cells. In addition, studies on the uptake of IONPs in 
cultures enriched in oligodendrocytes, ependymal cells or microglia will give estimates 
on how efficient these cell-types take up IONPs. 
 
Since IONPs were already clinical used in the brain, in vivo studies will be a key issue 
to address the fate of such particles in the brain. A recent report by Wang and 
colleagues investigated the distribution and clearance of IONPs infused into the rat 
striatum (Wang et al. 2011) with the result that dextran-coated IONPs freely diffuse 
through the interstitial space of the brain and were cleared from the site of infusion in 
about 2 weeks. Detailed analysis of the metabolic effects of such particles on the 
different types of brain cells are not given so far and represent thus a big challenge for 
future investigations of consequences of the presence of IONPs in the brain. 
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